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Cardiovascular diseases have been one the leading killers among the human 
population worldwide. During neonatal development, cardiomyocytes in men, mice 
and rats undergo a transition from hyperplastic to hypertrophic growth, so any further 
increases in myocardial mass are not accompanied by cardiomyocyte proliferation 
and the loss of the cardiac cells cannot be replenished. For decades, scientists have 
focused on elucidating the molecular events underlying the rapid switch from 
hyperplasia to hypertrophy in heart development. 
Previously, Anisimov and his group isolated a number of EST clones that were 
differentially expressed during differentiation of P19 embryonic stem cells to 
cardiomyocytes by serial analysis of gene expression (SAGE) and cardiac transcripts. 
One of the isolated clones was interferon-inducible transmembrane protein (IFITM) 
1，which is predominately expressed in heart tissues. IFITM 1, which is induced by 
interferons, was first identified to encode a T-cell surface antigen Leu-13. Together 
with the other two family members, IFITM2 and IFITM3, they correlate to inhibition 
of cell growth in cancer cells and immune cells and play a role in development in 
mice. Therefore, we hypothesized that the IFITM family might be involved in the 
control of proliferation in heart development and therefore characterized and studied 
the three IFITM members in cardiac cells. 
We observed upregulation of IFITM 1, IFITM2 and IFITM3 during Sprague-Dawley 
rat myocardial development and differentiation of H9C2 cardiomyoblasts. Because 
of the interferon-inducible property of IFITM 1 and IFITM3 genes in H9C2 cells, the 
effects of interferons-a, p and y on DNA synthesis in myoblasts were examined. As a 
i 
result, interferon-a and interferon-p were demonstrated to inhibit DNA synthesis. 
Overexpression of IFITMl also reduced DNA synthesis in the cardiac cells. 
Furthermore, an increased degradation of P-catenin, which is a key component of the 
Wnt signaling, was shown in the IFITMl, IFITM2 and IFITM3-transfected 
myoblasts. To summarize, the IFITM family proteins may be associated with the cell 
cycle arrest in cardiac cells and Wnt pathway, and further investigations will 
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Chapter 1 
Introduction 
1.1 Research initiative and significance 
Cardiovascular disease is one of the major killers among the human population in the 
world. According to the World Health Report in 2003, an estimated of 16.6 million, 
or one-third of the total global deaths resulted from the various forms of 
cardiovascular disease. Out of the 16.6 million deaths from cardiovascular disease, 
the major portion of the deaths came from ischemic heart disease. From the statistics 
carried out by the Department of Health, heart diseases claimed more than 5 thousand 
deaths and they were the second commonest cause of deaths in 2004 in Hong Kong. 
Besides, heart is occasionally exposed to ischemia during surgery and angina pectoris, 
causing cellular damage and cell loss. 
During neonatal development, cardiomyocytes in man, mouse and rat undergo a 
transition from hyperplastic to hypertrophic growth shortly after birth (Club and 
Bishop, 1984; Oparil et al, 1984; Li et al.，1996), so further increases in myocardial 
mass are not accompanied by cardiomyocyte proliferation and the loss due to 
ischemia cannot be compensated. For the time being, the exact mechanism that 
underlies this rapid switch from hyperplastic to hypertrophic growth of 
cardiomyocytes in mammalian heart remains largely unknown (Olson and Srivastava, 
1996; Anversa and Kajstura, 1998). Therefore, a thorough understanding of the 
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mechanism that regulates the withdrawal from the cell cycle and the development of 
approaches to reactivate proliferation and differentiation of mammalian 
cardiomyocytes will be of tremendous therapeutic value. For this reason, many 
scientists aim at elucidating the changes in gene expression during the rapid switch 
from hyperplasia to hypertrophy during myocardial development. 
A previous study reported a number of differentially expressed genes during 
differentiation of P19 embryonic stem cells to cardiomyocytes by serial analysis of 
gene expression (SAGE) (Anisimov et al, 2000). One of the EST clones 
GAGGACTCAA (Accession No: AK004121) was isolated to have altered 
expressions in cardiac transcripts. This EST clone corresponds to mouse 
interferon-inducible transmembrane protein 1 (IFITMl). In this project, IFITMl 
together with two of its family members, IFITM2 and IFITM3 were characterized 
and studied in H9C2 cells. Because of the interferon-inducible property of this 
IFITM gene, the effects of interferons would also be examined in H9C2 cells. 
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Hypertensive 
and Other CDVs Ischaemic Heart 
(3.9 M i l l i o n ) ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Disease 
^ ^ ^ ^ ^ ^ ^ ^ (7.2 
Cerebrovascular ^ ^ ^ ^ ^ ^ ^ ^ ^ 
Disease 
(5.2 Million) 
Total CDVs Deaths (16.6 Million) 
Figure 1.1 Estimated deaths attributed to cardiovascular diseases in 2001, from 
the World Health Report in 2003. A total of 16.6 million of deaths resulted from 
different forms of cardiovascular diseases in the World. 
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1.2 Terminal differentiation 
According to a classic concept, terminally differentiated cells can be defined as cells 
that have definitively lost their ability to divide in the process of acquiring 
specialized functions. Terminally differentiated cells are distinct from resting or 
quiescent cells in that growth arrest in the latter is，by definition, reversible. Upon 
appropriate stimulation, some of the cells that reside in the quiescent GO phase can 
re-enter the cell cycle and proliferate again. For example, after partial hepatectomy 
or severe injury in liver, liver cells can be regenerated by proliferation of mature 
hepatocytes as well as biliary epithelial cells and fenestrated endothelial cells 
(Michalopoulos and DeFrances, 1997). 
On the other hand, terminally differentiated cells cannot re-enter the cell cycle and 
lose the ability to divide again. Examples of the terminally differentiated cells are 
neurons, skeletal and cardiac muscle cells, white fat adipocytes and most 
hematopoietic and epithelial cells in their final stages of differentiation. Skeletal 
muscle cells constitute a classical example of terminal differentiation. These cells 
have never been observed to divide spontaneously in vitro or in vivo. However, their 
cell cycle machinery is intact and can be reactivated under appropriate experimental 
conditions. Myoblasts can be induced to differentiate by growth factor withdrawal in 
vitro (Okazaki and Holtzer, 1966). Also, terminally differentiated adipocytes retain 
the proliferative potential and are able to re-enter the cell cycle by adenovirus 
infection (Crescenzi et al., 1995). 
4 
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1.3 Controversial terminal differentiation in 
cardiomyocytes 
During the neonatal period, mammalian cardiomyocytes lose their ability to 
proliferate and exit the cell cycle in vivo (Anervsa et al, 1996/ To respond to growth 
stimuli and perform physiological functions, the expansion of cardiac mass 
postnatally is accomplished by hypertrophy (Aschoff, 1921; Kaufmann, 1922; 
Karsner et al, 1925). 
However, the notion of terminal differentiation in mammalian cardiomyocytes is still 
debatable (Anversa and Kajstura, 1998). Evidence has shown that cardiomyocytes 
maintain a low but measurable level of DNA replication beyond the prenatal period 
in rats (Overy and Priest, 1966; Cheng et al, 1995) and human (Quaini et al., 1994). 
In addition, mitosis in 2-month-old rats (Overy and Priest, 1966) and a significant 
increase in myocyte number in both ventricles with maturation in human (Iversen et 
al, 1968; Adler and Constabel, 1975; Adler and Constabel, 1980; Olivetti et al., 1991; 
Olivetti et al., 1995) have been documented. 
In summary, the concept of the heart as a terminally differentiated organ unable to 
replace working myocytes has been at the centre of cardiovascular research and 
therapeutic developments for the past decades. It is clear that the adult mammalian 
myocardium lacks sufficient regenerative capacity to restore the pump function after 
myocardial infarction or after chronic myocyte loss to apoptosis in heart failure and 
injuries (MacLellan and Schneider, 2000). Although adult myocardium has been 
shown to have a small population of progenitor cells (Oh et al., 2004), the accepted 
5 
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view remains that myocytes do not proliferate once they have become differentiated. 
Therefore, the heart reacts to an increase in workload only by hypertrophy of the 
existing cardiac myocytes during postnatal maturation, adulthood and senility. 
6 
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1.4 Molecular switch from hyperplasia to 
hypertrophy in neonatal myocardial 
development 
During neonatal development in rats, cardiomyocytes undergo a transition from 
hyperplastic to hypertrophic growth within the first two weeks after birth (Li et al, 
1996). The expansion of myocardial mass typically is not accompanied by 
cardiomyocyte proliferation (Soonpaa and Field, 1998). Therefore, cardiomyocytes 
respond to growth stimuli, increased workload, and injury mainly by hypertrophy. 
Currently, the exact mechanism that underlies this rapid switch from hyperplasia to 
hypertrophy of cardiac myocytes in the mammalian heart remains largely unknown 
(Olson and Srivastava，1996; Anversa and Kajstura, 1998). It has been shown that the 
activity of cardiomyocyte DNA polymerase-a (Limas and Limas, 1978), the 
expression of PCNA (Marino et cd., 1991)，cyclin A (Yoshizumi et al., 1995), cyclin 
D1 (Soonpaa et al, 1997)，cyclin D2，cyclin D3 and cyclin E (Flink et al” 1998) as 
well as the kinase activity and expression of cdk2 and cdk4 (Brooks et al., 1997; 
Kang and Koh, 1997) decrease during the first postnatal weeks. In addition, complex 
formation between E2F and pi30 and a low level of retinoblastoma protein in 2-day 
neonatal myocytes (Flink et al., 1998) have been demonstrated. However, despite all 
these data, the molecular mechanism underlying the cell cycle arrest in adult 
cardiomyocytes is still unclear. 
7 
Chapter 1 ： Introduction 
1.5 Interferons 
Interferons are multifunctional cytokines that play key roles in mediating antiviral, 
antiproliferative and immune-modulating responses (Der et ah, 1998; Goodboum et 
al., 2000; Reder, 2000; De Veer et aL, 2001; Servant et al., 2002; Kerr et aL, 2003). 
There are two basic types of interferons: type I interferons (a and p predominately) 
are encoded by a large family of genes (Weissmann and Weber, 1986) and secreted 
principally by leukocytes (a) and fibroblasts (P) and are induced directly in response 
to a viral infection; type II interferons (y), which are structurally unrelated and 
encoded by a single gene (Gray and Goeddel, 1982), are synthesized by 
T-lymphocytes or natural killer cells following detection of infected cells by antigen 
presentation. 
Type I and type II interferons signal through distinct but related pathways (Stark et 
al” 1998). They bind to their cognate receptors, which bind to the Janus kinases 
(JAKs) and the signal tranducers and activators of transcriptions (STATs) (Ihle and 
Kerr, 1995; Darnell, 1996; Ihle, 1996; Sen and Ransohoff, 1997; Darnell, 1998). 
These in turn initiate a signaling cascade that eventually leads to the transcriptional 
induction of at least 70 genes whose products mediate interferon actions such as 
inhibition of proliferation (Der et al, 1998; Certa et al., 2001). 
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1.6 Functions induced by interferons 
Interferons are cytokines that play several fundamental roles in body defense against 
viral and parasite infection and exhibit antiproliferative and differentiating activities 
(Der et al., 1998; Goodbourn et al., 2000; Reder, 2000; De Veer et al, 2001;Servant 
et al” 2002; Kerr et al, 2003). 
The ability of interferons confer an antiviral state on cells is essential for the survival 
of higher vertebrates because they provide an early line of defense against viral 
infections. This vital role has been demonstrated by the exquisite sensitivity to virus 
infections of mice lacking of interferons-a/p and y receptors (Van den Broek et al., 
1995) and inhibition of virus replication by interferons (Vilcek and Sen, 1996). 
Besides, interferons are known to profoundly affect nearly all phases of innate and 
adaptive immune responses. Within the interferon family, interferon-^ plays the 
predominant immunomodulatory role. It is produced by T cells and natural killer 
cells in response to immune and inflammatory stimuli, which in turn stimulates the 
development and actions of immune effector cells to resist foreign particles and 
infections (Goodbourn et al, 2002). 
Other than body defense, interferon-a/p affects cellular development and 
homeostasis. In the bone marrow, type I interferons are weakly produced and 
regulate the homeostatic differentiation of hematopoietic cells, such as B cells, T 
cells, osteoclasts and myeloid dendritic cells (Lin et al, 1998; Taniguchi and 
Takaoka, 2001; Takayanagi et al, 2002; Honda et al., 2004; Ichikawa et al., 2004). 
Although the underlying mechanisms are still unknown, in most cases, interferon 
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signaling negatively affects hematopoietic cell development. 
In addition, interferons are involved in control of apoptosis, with either pro- or 
anti-apoptotic activities which depend on factors such as the state of cell 
differentiation. For instance, interferon-丫 either induces or inhibits the apoptosis of 
murine pre-B cells or B-chronic lymphocytic leukemia cells respectively (Buschle et 
al,, 1993; Grawunder et al, 1993; Rojas et al, 1996). Similarly, interferon-y 
promotes either proliferation or apoptosis in malignant human T cells, depending on 
the presence or absence of serum and the levels of the interferon-y receptor (Novelli 
et al, 1994). 
Moreover, interferons have been demonstrated to inhibit cell growth, even though 
exhibiting various degrees of sensitivity to the antiproliferative activity in different 
cells in vitro. In some cases, growth arrest may be due to differentiation, particularly 
when interferons are used in combination with other agents such as retinoids 
(Higuchi et al, 1991; Nason-Burchenal et al, 1996). Although specific 
interferon-induced genes have not been linked directly to the antiproliferative activity, 
interferons have been shown to target specific cell-cycle regulatory components, 
including c-myc, retinoblastoma protein (pRB), cyclin D3 and cdc25A (Kumar and 
Atlas, 1992; Resnitzky et al., 1992; Melamed et al, 1993; Tiefenbrun et al., 1996). 
In lymphoblastoid Daudi cells, interferon-a leads to a rapid shutdown of c-myc 
transcription, possibly through a decrease in the activity of the transcription factor 
E2F (Melamed et al, 1993). Ml myeloid leukemia cells transfected with an inactive 
mutant of RNA-activated kinase failed to suppress c-myc in response to type I 
interferons, although the phosphorylation of pRB is suppressed (Raveh et al., 1996). 
The phosphorylation of pRB by interferons is suppressed by the inhibition of cdk4 
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and cdk6. This inhibition is achieved through suppression of cyclin D3 and by 
preventing the activation of cdk2-cyclin A and cdk-cyclin E, thereby inhibiting the 
phosphatase cdc25A (Melamed et al.’ 1993). 
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1.7 Interferons in cardiomyocytes 
The roles of interferons in heart have not been extensively explored. Most of the 
current studies of interferons in cardiomyocytes focus on cardiac protection against 
viruses. 
Interferons contribute to the cardiac protective response against viral infections. Viral 
myocarditis is an important human disease and often fatal in infants. It can progress 
to chronic myocarditis, dilated cardiomyopathy and cardiac failure. Evidence has 
shown that interferons play an important role in the antiviral defense against 
coxsakievirus B3-induced myocarditis (Kandolf et al., 1985; Matsumori et al., 1988; 
Wessely et al.’ 2001; Deonarain et al, 2004; Wessely, 2004). Moreover, interferons 
are involved in cell-mediated autoimmunity in viral myocarditis. Interferon-y 
induced gene expression for intercellular adhesion molecule-1 (ICAM-1), vascular 
cell adhesion molecule-1 (VCAM-1)，and endothelial leukocyte adhesion molecule-1 
(ELAM-1) in cultured neonatal rat cardiac myocytes (Seko et al., 1996; Hattori and 
Kasai, 1997). 
Besides, there is a growing body of evidence that interferon-y plays a critical role in 
cardiomyocyte apoptosis in vitro. Interferon-y induces apoptosis in cardiac cells 
through STAT-1 activation under the serum-free condition (Stephanou et al., 2000). 
Additionally, incubation of serum-starved neonatal rat ventricular myocytes with 
interleukin-lp and interferon-y results in programmed cell death, together with an 
increase in nitric oxide synthase expression and nitrite production (Arstall et al., 
1999). 
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1.8 Interferon-inducible transmembrane gene 
family 
Up till now, five members of the rat interferon-inducible transmembrane (IFITM) 
family have been identified, IFITM 1, IFITM2，IFITM3，IFITM5 and IFITM6. 
Several homologues exist in human, cows and rats and they are all conserved 
amongst mammalian species (Lewin et cd., 1991; Lange et al, 2003). The IFITM 
gene family is highly inducible by both type I (a and P) and type II (y) interferons in 
immune cells, epithelial cells and fibroblastic cells (Friedman et al., 1984; Kelly et 
al., 1985). However, much of what is known about the function of this family of 
proteins comes from the limited work on the human homologue of IFITM 1. 
IFITM 1 is the only one of the family members that has been partially studied and the 
expression at protein level and the functions of the other family members remain 
unexplored. IFITM 1 was first identified to encode a T-cell surface antigen named 
Leu-13 (Chen et al, 1984). Leu-13 is expressed in many tissues, including 
vasculature, epithelia of the renal proximal tubules, non-keratinaized basal epithelia 
of the cervix, esophagus, medullary thymocytes and placental trophoblasts 
(Pumarola-Sune et al, 1986). The cell surface antigen has been suggested to be 
involved in the transduction of antiproliferative and homotypic adhesion signals 
(Bradbury et cd., 1993; Deblandre et cd., 1995). 
In B cells, for example, Leu-13 is a part of a putative signaling surface receptor 
complex together with CD21, CD 19 and CD81, triggering the antiproliferative 
activity (Bradbury et al, 1993). In B cell lymphomas, induction of the IFITM 1 gene 
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correlates with the sensitivity of interferon-induced inhibition of cell growth (Evans 
et al, 1993). In addition, IFITM family genes are often downregulated when 
proliferation rates increase. Transcript levels of IFITM 1, for example, are low in 
leukemia B cells, compared to normal B lymphocytes and downregulation of 
IFITM 1 and IFITMS correlates with brain tumor progression (Evans et al, 1993; 
Huang et al., 2000). In a murine mast cell tumor model, expression of mouse 
IFITM3 is consistently downregulated in tumors, compared to the untransformed 
precursor cell line (Brem et al., 2001). Moreover, a decrease in the expression level 
of a rat homology of IFITM3 has been observed after ras transformation of rat 
fibroblasts (Zuber et al., 2000). In contrast, IFITMl, IFITM2 and IFITM3 are 
significantly upregulated in human colorectal tumors and suggested to be the 
diagnostic markers in these tumors (Andreu et al, 2006). 
Other than that, the IFITM family plays a critical role in development in mammals. 
IFITM3 was first isolated from a genetic screen aimed at identifying the genes 
involved in the acquisition of germ cell competence (Saitou et aL, 2003). Later, the 
three members of the IFITM family, IFITMl, IFITM2 and IFITM3, have been 
demonstrated to exhibit expression which is associated with germ cell specification 
and development in mice (Lange et aL, 2006). Other than that, IFITM3 is necessary 
to mammary epithelial cell differentiation in vitro, by recruiting to lipid membrane 
domains (Zucchi et aL, 2003). 
Besides the functional studies on the IFITM gene, the tissue distribution of IFITMl 
and IFITM3 has been investigated. As shown by Northern blot analysis, IFITMl is 
expressed in many adult tissue types in mice, including lung, testis, brain and kidney 
and most predominantly expressed in heart (Anisimov et al., 2002). On the other 
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hand, IFITM3 is expressed at low levels in kidney and muscle, but not in brain and 
testis. Significant expression has been observed in lung, heart, and kidney (Zucchi et 
al., 1998). The dominant expression of IFITM 1 and IFITM3 in heart suggests that 
they may be important for the heart function. 
To summarize, the IFITM family is apparently not only involved in host defense, but 
also critical in the developmental process and in the control of cell proliferation. 
Moreover, they may play a significant role in heart. 
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1.9 Our hypothesis and objective 
Heart disease has been one of the major killers among the human population 
worldwide. For decades, the mechanisms that regulate terminal differentiation in 
adult cardiomyocytes still remain unclear and the cellular loss cannot be replenished. 
Therefore, the elucidation of the machinery that controls proliferation during 
myocardial development may shed light on heart regeneration and will be of 
remarkable value. 
Interferons are multifunctional cytokines that contribute to host defense against viral 
and parasite infection, antigrowth and differentiating activities, and modulating 
immune responses. On the other hand, type I and type II interferons induce the 
IFITM gene family, which play important roles in induction of homotypic adhesion 
of cells, development, differentiation and the control of proliferation. One of the 
family members, IFITM 1，has been identified to upregulate during differentiation of 
PI9 embryonic stem cells to cardiomyocytes and cardiac transcripts. It is not only 
demonstrated to have altered expressions in fetal and adult hearts, but also in brain, 
intestine, kidney and lung tissues (Anisimov et al” 2002). In addition, IFITM 1 and 
IFITM3 express predominately in adult heart tissues (Zucchi et al, 1998; Anisimov 
et al, 2002). Our findings also demonstrated differential expressions of IFITM 1, 
IFITM2 and IFITM3 during rat myocardial development and differentiation of H9C2 
cells. 
Based on these findings, we hypothesize that the three members of the IFITM gene 
family, IFITM 1，IFITM2 and IFITM3, are important in heart development and 
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involved in the control of proliferation in rat cardiomyocytes. Therefore, in our 
project, the roles of IFITMl, IFITM2, IFITM3 and interferons on cardiac 
proliferation were studied in H9C2 cells. If the IFITM gene family contributes to 
mammalian heart development, this may give insights to therapeutic approaches to 
treat cardiovascular diseases and heart regeneration. 
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Chapter 2 
Materials and Methods 
2.1. Sequence analysis 
We analyzed the primary structure of IFITM 1, IFITM2 and IFITM3 using ProtParam 
(http://ca.expasy.org/tools/protparam.html) and NCBI Entrez Gene 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene). Location 
of transmembrane domains was analyzed by TMHMM2.0 
(http://www.cbs.dtu.dk/services/TMHMM-2.0/). Nucleotide and amino acid 
sequences were aligned by Blast 2 Sequences 
(http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi). Potential phosphorylation 
sites were analyzed by NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/). 
Conserved domains were predicted by NCBI Conserved Domain Search 
(http ://www.ncbi. nlm. nih. gov/Structure/cdd/wrpsb. cgi). 
2.2 Cell culture 
The cell line H9C2 was obtained from the American Type Culture Collection (ATCC) 
(ATCC No: CRL-1446) and grown in a monolayer culture in Dulbecco's modified 
Eagle's medium (DMEM) (Sigma) supplemented with 10% (v/v) heat-inactivated, 
certified fetal bovine serum (FBS) (HyClone), and 1% (v/v) antibiotics (penicillin, 
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lOOU/ml; streptomycin sulfate, lOO^g/ml) at 37°C in 5% CO2 in a humidified 
atmosphere. Myoblasts were passed and harvested before reaching the confluent state. 
All experiments were done using cells between 5-20 passages. 
2.3 Induction of differentiation of H9C2 cells 
In brief, 5x10^-6x10^ H9C2 cells were seeded on 100mm dish and grown for 2-3 
days. When the cell confluence reached 70-80%, the complete medium was replaced 
by low serum differentiation medium [DMEM containing 1.5% (v/v) horse serum 
(HS) and 0.5% (v/v) antibiotics (penicillin, lOOU/ml; streptomycin sulfate, 
1 OOiig/ml)] and grown for 2, 4，6 and 8 days. 
2.4 In vitro induction of IFITMs by interferon 
treatments 
H9C2 cells were incubated in DMEM medium with interferon-a (lOOU/ml，200U/ml, 
500U/ml) (Sigma), interferon-P (lOOU/ml, 200U/ml, 500U/ml) (Sigma), and 
interferon-Y (10r|g/ml, 20r|g/ml, 40r|g/ml, 100r|g/ml) (Sigma) for 24 hours under 
standard conditions. After each treatment, the cells were harvested for total RNA 
extraction, protein isolation or subjected to proliferation assays. 
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2.5 RNA isolation 
2.5.1 Experimental animals and sampling 
Sprague-Dawley rats of different ages were obtained from the animal facilities of our 
university. Hearts were carefully dissected from decapitated animals and rinsed in 
diethyl pyrocarbonate-treated phosphate buffered saline (DEPC-PBS). Only the 
lower two-thirds of the myocardium were isolated. The ventricles were flash-frozen 
in liquid nitrogen to avoid RNA degradation. 
2.5.2 Total RNA isolation 
Total RNA was extracted using the TRIZOL Reagent (Invitrogen). For heart tissues, 
ventricles were homogenized in TRIZOL regent at SOOOrpm for 5 seconds and then 
on ice for 5 times by a Kika Labortechnik T25 Basic homogenizer. The homogenate 
was aliquoted into 1.5ml eppendorfs, which would immediately subjected to RNA 
extraction or stored at -80°C until use. For cells after induction of differentiation, 
transfection or interferon treatments, they were lysed in TRIZOL Reagent. Genomic 
DNA in cells or homogenates was removed by saving the supernatant after 
centrifugation at 12000g at 4°C for 10 minutes for 2 times. RNA and proteins were 
separated from genomic DNA by precipitation in chloroform at room temperature for 
2 minutes and then centrifugation at 11400g at 4°C for 15 minutes. The upper layer 
with RNA and proteins was saved and added to isopropanol to precipitate RNA at 
room temperature for 10 minutes. Then, proteins were removed by centrifugation at 
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11400g at 4°C for 10 minutes and discarding the supernatant. The pellet was washed 
with 70% precooled ethanol，centrifuged at 12000g at 4°C for 5 minutes, dried at 
70�C for 5 minutes, eluted in 30fxl-80|il DEPC-treated water and then on ice 
immediately for 2 minutes. The products were stored at -80°C until use. 
2.5.3 RNA quantification and quality check 
RNA concentrations were spectrophotometrically determined by absorbance at 
260nm. To check the quality of the RNA samples, 2|il of each sample was run on a 
1% agarose gel stained with ethidium bromide. For intact RNA samples, the band 
intensities of 28S and 18S were in a ratio of 2:1 and the ratio of absorbance at 260nm 
and 280nm was between 1.8 and 2.0. 
2.5.4 Purification by Qiagen-RNeasy column and 
DNase I digestion 
Trace amounts of genomic DNA could also be detected by real-time PGR and 
interfere the reliability of the results. To remove the residual genomic DNA from the 
RNA samples, 4|ig of each sample was further purified by RNeasy columns (Qiagen) 
and then digested by 4U DNase I (Invitrogen) under IX DNase I Reaction Buffer 
pOOmM Tris-HCl (pH 8.4)，20mM MgCb, 500mM KCl] (Invitrogen) at room 
temperature for 15 minutes. To inactivate the DNase I, 4|il of 25mM EDTA was 
added and the samples were heated at 65�C for 10 minutes. 
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2.5.5 First-strand cDNA synthesis 
The first-strand cDNA was synthesized from total RNA by oligo (dT) primer and 
reverse transcriptase (RT) with the first-strand synthesis kit from Thermoscript 
RT-PCR System III (Invitrogen), according to the manufacturer's instructions. 
Briefly, 4|ag purified RNA was first mixed with 4\x\ of 50mM oligo (dT) primer and 
4|il of lOmM dNTPs and added to a total volume of 52|il. The reaction mixture was 
denatured at 65°C for 5 minutes and then on ice for 1 minutes. Then cDNA synthesis 
reaction mix, containing 5X synthesis buffer, 0.1 M DTT，4U Reverse transcriptase 
(RT), 4U RNaseOUT was added to RNA and cDNA synthesis reaction was 
proceeded for 1 hour at 55°C and an heat-inactivation step at 70°C for 15 minutes. 
An optional step was carried out, removal of RNA templates by lOU RNase H 
(Gibco) for at 37°C 20 minutes. Then the first-strand cDNA was stored at -20°C until 
use. 
2.7 Quantitative real-time polymerase chain 
reaction (Real-time PCR) 
Reat-time PCR analyses were carried out with the Prism 7500 Fast System Sequence 
Detection System (Applied Biosystems). PCR primers were designed with the 
software GeneTool and the sequences were listed in Table 2.1. Cycling reaction 
conditions consisted of the following: 50°C for 2 minutes, 95°C for 10 minutes, 
followed by 95�C for 15 seconds and 60�C for 1 minute cycled 40 times. Reactions 
were performed in 96-well MicroAmp Optical plates (Applied Biosystems) in a final 
volume of 20^1. Each reaction mix included Ijil or 2|il cDNA templates, 0.625|iM 
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forward and reverse primers and IX Power SYBR Green Reaction Mix (Applied 
Biosystems). Glyceraldehyde-3-phosphate-dehydrogenase or P-actin was used to 
normalize the cDNA templates in each panel. Non-template controls were included 
in each plate. After the amplification, the PGR products were subjected to the 
following dissociation: 95°C for 15 seconds, 65°C for 1 minute and 95°C for 15 
seconds, in parallel 5|al of the products being electrophoresized on an agarose gel. 
All data were analyzed by the SDS 1.3.1 software (Applied Biosystems). 
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Gene Name Forward and Reverse Primers 
F: 5，- GGCAATGAGCGGTTCCGAT-3 ‘ 
B-actin 
R: 5’-TGCCTGGGTACATGGTGGT-3， 
Interferon-inducible Transmembrane F: 5'-CAACCACCACAATCAACATG-3’ 
Protein 1 (IFITMl) R: 5'-TGGGGTAAACAGGCAGGACT-3' 
Interferon-inducible Transmembrane F: 5'-CGGTAGTCTTTCAGTCGCTTTC-3' 
Protein 2 (IFITM2) R： 5'-TGTGGACAGATATACGAAGGT-3 ‘ 
Interferon-inducible Transmembrane F: 5 '-CTGTCGTCATCATTGCTCTTA-3, 
Protein 3 (IFITM3) R： 5'-ATGGCTATCAAGTGCGTTTTAT-3' 
Glyceraldehyde-3-phosphate F: 5 '-TGCTGAGTATGTCGTGGAGT-3 ‘ 
Dehydrogenase (GAPDH) R: 5'-GGCTAAGCAGTTGGTGGTG-3 ’ 
Myosin Light Chain Ventricular F: 5，-AGCTCCAACGTGTTCTCCATGTTTGA-3’ 
Isoform 2 (MLC-2V) R: 5 ’-CCCAAACATGGTGAGGAACACAGTGAA-3 ’ 
Proliferating Cell Nuclear Antigen F: 5'-GCGAGTGGGGAGCTTGGCAAT-3' 
(PCNA) R: 5 '-AAGACCTCAGAACACGCTGGC-3 ‘ 
Table 2.1 Forward and Reverse Primer Sequences of Genes Studied in Real-time 
PCR 
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2.8 Cloning protocol 
2.8.1 Construction of pEGFP-IFITMl， 
pEGFP'IFITM2 and pEGFP-IFITM3 
fusion proteins 
2,8.1.1 Amplification of DNA fragments 
To construct GFP fusion proteins, the coding regions of rat IFITM 1，IFITM2 and 
IFITM3 were amplified by the primers containing BamUl and HindiW cleavage sites 
and the sequences of the primers were listed in Table 22. 
Each PGR reaction mix consisted of l-2|il rat heart cDNA template, IX PicoMaxx™ 
High Fidelity PGR Master Mix (Stratagene) and 0.5|iM forward and reverse primers 
in a total volume of 50|LI1. The thermal cycling profile was as follows: denaturation at 
95°C for 3 minutes, followed by 24 cycles of denaturation at 95°C for 36 seconds, 
annealing at 58°C for 36 seconds and extension at 72°C for 45 seconds. A final 
extension step was given at 72°C for 10 minutes. The thermal cycling reaction was 
performed in a PTC-100 or PTC-200 programmable thermal cycler (MJ Research). 
After the PGR reaction, the PGR products were run on a 1% agarose gel stained with 
ethidium bromide. 
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2.8.1.2 Purification ofPCR product 
The PGR products were purified by QIAquick Gel Extraction Kit (Qiagen) according 
to the manufacturer's protocol. The PGR products were first run on a 1% TAE 
agarose gel stained with ethidium bromide and the bands with the correct size were 
cut out. The gel slice was melted in approximately 3 volumes of QG buffer at 55°C 
for 10 minutes until it was completely dissolved. Then, one volume of isopropanol 
was added and mixed well with the sample. To bind the DNA, the sample was loaded 
to a QIAquick spin column which was centrifuged at ISOOOrpm for 1 minute and the 
flow-through was discarded. After that, the spin column was washed with 0.7ml PE 
buffer and centrifuged at ISOOOrpm for 1 minute again. The spin column was dried at 
70°C for 3 minutes to remove the residual ethanol in the PE buffer. Finally, 30^1 
prewarmed sterile water was added to the centre of membrane for elution and the 
spin column was centrifuged at ISOOOrpm for 2 minutes again. The eluted DNA was 
stored at -20°C until use. 
2.8. L 3 Restriction endonuclease digestion 
The purified PGR products and the cloning vectors, pEGFP-Nl (Clontech) and 
pEGFP-C 1 (Clontech), were digested with restriction enzymes, BamWl and Hindill. 
Each digestion reaction consisted of IX K Buffer (Amersham), 20U of BamYll (New 
England Biolabs)，20U of Hindill (Amersham) and 28|il purified PGR products or 
about 5|ag cloning vector in a total volume of 40fil. The digestion reactions were 
incubated at 37°C for 3 hours in a thermocycler. Negative controls were performed at 
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the same time. 
2.8.1.4 Insert/vector ligation 
After restriction digestion, the digested PCR products and the cloning vectors were 
run on 0.8-1% agarose gels and the gel slices were purified again as described in 
section 2.8.1.3. The eluted PCR products were concentrated to approximately \5\xl 
In each ligation reaction, it had IX T4 DNA ligase buffer (New England Biolabs)， 
3|il concentrated digested PCR product, 1|LI1 digested cloning vector and 400U of T4 
DNA ligase (New England Biolabs) in a total volume of 10|LI1 and incubated at 16°C 
overnight. A negative control and a self-ligation control were performed at the same 
time. 
2.8.1.5 Preparation of chemically competent 
bacterial cells 
Chemically competent bacterial cells DH5a were prepared by the Hanahan method 
(Hanahan, 1983). A single colony of E. coli strain DH5a was inoculated in 10ml 
Luria-Bertani (LB) medium and then incubated at 37�C for 16-20 hours with shaking 
at 250rpm. On the next day, 5ml of the inoculum was subcultured into 250ml LB 
medium and incubated at 37°C for about 3 hours with shaking at 250rpm until the 
absorbance at wavelength 600nm reached 0.3. The bacterial cells were then 
centrifuged at 3500rpm at 4°C for 10 minutes. The supernatant was discarded and the 
pellet was resuspended in 83ml ice-cold sterile RFl [lOOmM RbCl, 50mM MnCb, 
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30mM potassium acetate, lOmM CaCh and 15% (w/v) glycerol, pH 5.8]. The cell 
suspension was chilled on ice for 15 minutes. After that, the suspension was 
centrifuged at 3500rpm at 4 � C for 10 minutes again. The supernatant was discarded 
and the pellet was resuspended in 20ml ice-cold sterile RF2 [lOmM MOPS, lOmM 
RbCl, CaCb • H2O and 15% (w/v) glycerol, pH 6.8]. The cell suspension was chilled 
on ice for 15 minutes and then aliquoted into 200|al for each fraction. The aliquoted 
competent cells were quickly frozen in liquid nitrogen and stored at -20°C. 
2.8.1.6 Transformation of ligation product into 
chemically competent bacterial bells 
DH5a 
Competent bacterial cells DH5a were thawed on ice for 15 minutes and the ligation 
product was added to the bacterial cells carefully, which was incubated on ice for 30 
minutes. Then, the competent cells were subjected to a heat shock at 42°C for 50 
seconds and immediately chilled on ice for at least 2 minutes. After that, SOOfil LB 
medium was added for bacterial recovery and incubated at 37°C for 1 hour with 
shaking at 250rpm. After 1 hour, the samples were centrifuged at 13000rpm for 2 
minutes and about 900pi of the supernatant was discarded. The cell pellet was 
resuspended in the remaining lOOfil LB medium and the cell suspension was plated 
on a LB agar plate with SO^g/ml kanamycin. The agar plate was incubated at 37°C 
overnight to allow the bacteria to grow. 
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2.8.1.7 Recombinant clone screening by PCR 
Single colonies were picked by pipette tips and each pipette tip was dipped into a 
PCR reaction mix. Each PCR reaction mix was composed of IX PCR buffer, 0.2mM 
dNTPs，0.08|iM gene-specific forward primer and cloning vector reverse primer, 
1.5mM MgCh and 0.2|LI1 Taq polymerase in a total volume of 25|LI1. The PCR profile 
was as follows: 95�C for 5 minutes, followed by 95�C for 36 seconds and 55�C for 36 
seconds and 72°C for 1 minute cycled 35 times with a final extension step of 72°C 
for 10 minutes. After the PCR amplification, 5|il of the PCR product was run on a 
1% agarose gel stained with ethidium bromide. Only the recombinant clones had an 
insert band on the agarose gel. 
2.8.1.8 Small-scale preparation of recombinant 
plasmid DNA 
Recombinant plasmid DNA was extracted by Rapid Plasmid Miniprep System 
(Marligen). A singly recombinant clone was inoculated in 4ml LB medium 
containing 30(ig/ml kanamycin and the inoculum was grown at 37�C overnight with 
shaking at 250rpm. The culture was then centrifuged at 1 SOOOrpm for 2 minutes and 
the supernatant was discarded. The cell pellet was resuspended in 250|il Cell 
Suspension Buffer. Then, 250|il Cell Lysis Solution was added to the cell suspension 
and mixed by inverting the tube gently for 5 times and the cells were lysed for 5 
minutes. After 5 minutes, 350|al Neutralization Buffer was added and mixed by 
inverting the tube gently for 5 times. Followed by this, the cell suspension was 
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loaded to a spin cartridge which was on a wash tube. The spin cartridge was 
centrifuged at ISOOOrpm for 1 minute and the flow-through was discarded. To wash 
the membrane of the spin column, 700|al Wash Buffer was added to the cartridge 
which was centrifuged at ISOOOrpm for 1 minute. The flow-through was discarded 
again and the cartridge was centrifuged at 13000rpm for 2 minutes to remove the 
residual ethanol. The spin cartridge was placed on a new 1.5ml eppendorf and 30fal 
prewarmed sterile water was added to elute the plasmid DNA. Finally, the cartridge 
was centrifuged at ISOOOrpm for 2 minutes again and the plasmid DNA was saved. 
2.8.1.9 Dideoxy DNA sequencing 
Recombinant plasmid DNA with the expected size insert was sequenced to check the 
identity and the reading frame. The sequencing reactions were done by TechDragon 
Limited. 
2.8.1.10 Large-scale preparation of recombinant 
plasmid DNA 
After successfully cloning the target genes, the recombinant bacterial plasmid DNA 
was prepared in a larger scale by HiSpeed™ Plasmid Midi Kit (Qiagen) according to 
the manufacturer's protocol. First, the recombinant bacterial plasmid DNA was 
transformed into chemically competent cells DH5a and plated on an agar plate with 
30|ig/ml kanamycin, followed by incubation at 37°C overnight. On the next day, a 
single colony was picked and inoculated into 150ml LB medium and incubated at 
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37°C with shaking at 250rpm overnight. On the third day, the cells were collected by 
centrifugation at 6000g at 4°C for 10 minutes and the supernatant was discarded. The 
cell pellet was resuspended in 6ml Cell Suspension Buffer PI and mixed by inverting 
gently for 5 times. Then, 6ml Buffer P2 was added to the cell suspension and mixed 
by inverting gently for 5 times and this was incubated at room temperature for 5 
minutes. Afterwards, 6ml Buffer P3 was added to lyse the cells and mixed by 
inverting gently for 5 times. Then, the lysate was poured into the QIAfilter™ Midi 
Cartridge, which had been screwed with a cap, and the mixture was incubated at 
room temperature for 10 minutes. During the incubation, 4ml Equilibrium Buffer 
QBT was added to the HiSpeed Midi Tip to equilibrate the column by gravity flow. 
Ten minutes later, the cap screwed to the cartridge was removed and the plunger was 
pressed to filter the cell lysate into the previously equilibrated HisSpeed Midi Tip. 
The cell lysate was allowed to flow through the tip by gravity flow. Followed by this, 
the HiSpeed Tip was washed with 20ml Washing Solution once. The DNA bound to 
the resin was eluted by 5ml Buffer QF and the eluted DNA was precipitated by 3.5ml 
isopropanol at room temperature for 5 minutes. The isopropanol and DNA mixture 
was poured into a 20ml syringe that had been attached to a QIAprecipitator^'^ and 
filtered. The QIAprecipitator™ was washed by 70% ethanol twice by pressing the 
plunger and removed from the 20ml syringe. The QIAprecipitator丁M was attached to 
a 5ml syringe. Lastly, 700|il prewarmed sterile water was added to the 5ml syringe to 
elute the bound DNA. 
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Gene Name Vector Forward and Reverse Primers 
Interferon-inducible pEGFP-Cl F: 5’-GCAAGCTTATATGCCCAAGGAACAGCAAGA-3’ 
Transmembrane 
Protein 1 (IFITM 1) pEGFP-Nl F: 5'-GCAAGCTTATGCCCAAGGAACAGCAAGAG-3 ‘ 
pEGFP-Cl F: 5'-GCGGATCCAGTGTTCTTTTAGTGGCGTAAA-3' 
pEGFP-Nl 
Interferon-inducible pEGFP-Cl F: 5'-GCAAGCTTATATGAGCCACAATTCCCAAGCCTTCTTG-3' 
Transmembrane 
Protein 2 (IFITM2) pEGFP-Nl F: 5'-GCAAGCTTATGAGCCACAATTCCCAAGCCTTCTTG-3' 
pEGFP-C 1 R: 5' -GCGG ATCC ATG A ATCC AG A ATGTGGCGTTC-3 ’ 
pEGFP-Nl 
Interferon-inducible pEGFP-Cl F: 5'-GCAAGCTTATATGAACCACACTTCTCAAGCCTTCGTG-3' 
Transmembrane 
Protein 3 (IFITM3) pEGFP-Nl F: 5'-GCAAGCTTATGAACCACACTTCTCAAGCCTTCGTG-3' 
pEGFP-Cl R: 5'-GCGGATCCATAGTCTGGAGACGAGGAGCAT-3' 
pEGFP-Nl 
Table 2.2 Sequences of Cloning Primers for Construction of IFITMl, IFITM2 
and IFITM3 GFP Fusion Proteins 
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2.8.2 Construction of IFITMl-pcDNA4, 
IFITM2-pcDNA4 and IFITM3-pcDNA4 
constructs 
2.8.2.1 Amplification of DNA fragments 
Rat IFITMl, IFITM2 and IFITM3 coding regions were amplified by the primers 
listed on Table 2.3. Each PCR reaction mixture consisted of IX PicoMaxx丁m High 
Fidelity PCR Master Mix (Stratagene), \\i\ rat heart cDNA template, 0.4|iM forward 
and reverse primers in a total volume of 50|il. 
2.8.2.2 Insert/vector ligation 
The insert was cloned into the pcDNA4 vector, with the use of pcDNA4/HisMax® 
TOPO® TA Expression Kit (Invitrogen). First, the PCR fragments were subjected to 
adenylation. A reaction mixture of 3.9|al concentrated PCR fragments, 0.1 Tag 
Polymerase, 0.5|il 2mM dATP and 0.5|al lOX PCR Buffer was incubated at 72°C for 
30 minutes in a thermocycler. Then, the PCR fragments with a stretch of A overhangs 
were mixed with 1 [i\ vector and 1 \x\ salt solution and ligated at room temperature for 
30 minutes. 
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2.8.2.3 Transformation of ligation product into one 
shot® TOPI OF, chemically competent E, 
coli cells 
The ligation product was added to One Shot® TOPI OF, chemically competent E. coli 
cells (Invitrogen) and incubated on ice for 20 minutes. Then, the ligation product was 
transformed into the competent cells by the same procedures as described in section 
2.8.1.6. 
The following cloning procedures including colony PCR screening for recombinant 
clones, small-scale preparation of bacterial plasmid DNA, sequencing, midi-scale 
preparation of bacterial plasmid DNA were the same as described in sections 
2.8.1.7-2.8.1.10. 
34 
Chapter 2: Materials and Methods 
Gene Forward and Reverse Primers 
Interferon-inducible F: 5 ‘ -CCC A AGGA AC AGC A AG AGGT-3 ‘ 
Transmembrane Protein 1 
(IFITM 1) R: 5'-CTATGTTCTTTTAGTGGCGTAA-3’ 
Interferon-inducible F: 5'-AGCCACAATTCCCAAGCCTTC TTGCCC-3' 
Transmembrane Protein 2 
(IFITM2) R:5'-CTAGAATCCAGAATGTGGCGTTCTTT-3' 
Interferon-inducible F: 5'-AACCACACTTCTCAAGCCTTCGTGAAC-3' 
Transmembrane Protein 3 
(IFITM3) R: 5'-TCAAGTCTGGAGACGAGGAGCATTAA-3' 
Table 2.3 Sequences of Cloning Primers for IFITMl-pcDNA4, IFITM2-pcDNA4 
and IFITM3-pcDNA4 Constructs 
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2.9 Transient transfection 
SxlO'^  H9C2 cells in plain DMEM were seeded on 12-well plates while 13x10^ cells 
in plain DMEM were seeded on 6-well plates 2 days before transfection. The cells 
were grown to 70-80% confluency to perform transfection. Transfection efficiency 
was assessed by the empty vectors pEGFP-C 1 and pEGFP-Nl and was about 
20-30%. 
Transient transfection was performed as described in the protocols of Lipofectamine 
Plus Reagents (Invitrogen). 400r|g plasmid DNA in 12-well plates and 2jig in 6-well 
plates plasmid DNA were used for each transfection. Plasmid DNA was first diluted 
with plain medium and then Plus reagent was added. This was incubated at room 
temperature for 15 minutes to allow the formation of pre-complexes. After that, 
Lipofectamine reagent diluted in plain medium was added and mixed by pipetting up 
and down. While this was further incubated at room temperature for 15 minutes, cells 
were washed with IX PBS once to remove serum that would inhibit complex 
formation and plain medium was added. After the 15 minutes incubation, the 
DNA-Plus-Lipofectamine complexes were added to the cells and incubated at 2>TC 
with 5% CO2. After 3 hours, the plain medium with the complexes were discarded 
and it was replaced by complete medium. Cells were transfected for 26-28 hours and 
collected for further studies. 
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2.10 Subcellular fractionation 
Proteins were isolated according to their subcellular localization, as described in the 
protocols of ProteoExtract® Subcellular Proteome Extraction Kit (Merck, Germany). 
Proteins were fractionated into four subcellular fractions: cytosol (Fraction 1), 
membrane and membrane organelles (Fraction 2)，nucleus (Fraction 3) and 
cytoskeleton (Fraction 4). 
3-5x10^ cells were trypsinized and harvested by centrifugation at 500g at 4°C for 5 
minutes, followed by washing with IX PBS once. The cell pellet collected was lysed 
in 1ml ice cold Extraction Buffer 1 with 5|il Protease Inhibitor Cocktail and 
incubated at 4°C for 10 minutes under gentle agitation. Then, the lysate was 
centrifuged at lOOOg at 4°C for 10 minutes and the supernatant (Fraction 1) was 
saved into a new tube. The sediment insoluble material was lysed in 1ml ice cold 
Extraction Buffer 2 with 5|il Protease Inhibitor Cocktail and incubated at 4°C for 30 
minutes under gentle agitation. Then, the lysate was centrifuged at 6000g at 4°C for 
10 minutes and the supernatant (Fraction 2) was saved into a new tube. After that, the 
sediment insoluble material was lysed in 500|il Extraction Buffer 3 with 5^1 Protease 
Inhibitor Cocktail and 1.5fil Benzonase® and incubated at 4°C for 10 minutes under 
slow rotation. The lysate was centrifuged at 7000g at 4°C for 10 minutes and the 
supernatant (Fraction 3) was saved into a new tube. Finally, the sediment insoluble 
material was suspended in SOOfil Extraction Buffer 4 with 5|il Protease Inhibitor 
Cocktail. The protein fractions were stored at -80°C until use. 
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2.11 Isolation of total proteins cell lysates 
H9C2 cells on either 6-well plate or 100mm dish were washed with ice-cold PBS, 
trypsinized at 37°C for 15 minutes and inactivated by DMEM. Cells were harvested 
by centrifugation at 4°C at SOOOrpm for 4 minutes and washed with ice-cold PBS for 
2 times. The pellet was resuspended and lysed in lysis buffer (50mM Tris [pH 8.0], 
0.3M NaCl, lOmM EDTA, 50mM NaF，0.1% SDS, 0.5% sodium deoxycholate, 1% 
NP40, 0.2mM PMSF and protease inhibitor cocktail) on ice for at least 15 minutes. 
Then, the cell debris was centrifuged down and the supernatant was saved and stored 
at -80°C in small aliquots. 
2.12 Protein concentration determination 
Protein concentration was determined by the bicinchoninic acid protein assay. 
Protein standards were prepared by 5mg/ml bovine serum albumin, with a 2-fold 
serial dilution. 3|il of the protein standards were added to a 96-well plate in 
duplicates. 200|il of a mixture consisting of bicinchoninic acid (Sigma) and 4% 
CUSO4 in a volume ratio of 49:1 was added to the proteins. Then, the 96-well plate 
was incubated at 37°C for 30 minutes to allow purple colour to develop. The 
absorbance of the coloured products at wavelength 540nm was measured by a 
Bio-Rad model 3550 96-well plate reader (Bio-Rad). A standard curve could be 
constructed by the known protein concentrations and the readings of the absorbance 
at wavelength 540nm. In this way, protein concentration of the samples could be 
determined by the same approach, with the use of the standard curve. 
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2.13 Protein gel electrophoresis and western 
blotting 
2.13.1 Preparation of SDS-polyacrylamide gel 
A SDS-polyacrylamide gel consisted of two layers: lower two-thirds of a running gel 
and upper one-third of a stacking gel. The running gel included 8-15% (v/v) 
acrylamide, 0.1% (w/v) APS, 0.1% (w/v) SDS, 0.375M Tris-Cl (pH 8.8) and 
TEMED while the stacking gel included 3% (v/v) acrylamide, 0.1% (w/v) APS, 0.1% 
(w/v) SDS, 0.126M Tris-HCl (pH 6.8) and 5|il TEMED. After polymerization of the 
SDS-polyacrylamide gel, the comb was removed from the stacking gel and the gel 
was placed in a gel tank filled with IX running buffer [25mM Tris-HCl, 250mM 
glycine, 0.1% (w/v) SDS, pH 8.3]. 
2.13.2 Preparation of protein samples 
Normalized protein samples were added to 2X SDS loading dye [0.5M Tris-HCl (pH 
6.8), 4.4% (w/v) SDS, 20% (v/v) glycerol, 2% (v/v) 2-mercaptoethanol, 2% (w/v) 
bromophenol blue] and then denatured at 100°C for 5 minutes. The protein samples 
were then on ice for 5 minutes. 
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2.13.3 SDS-polyacrylamide gel electrophoresis 
25-30|ag protein samples, in parallel with 10|4,1 Seeblue Plus2 Pre-stained Standard 
marker (Invitrogen) were loaded to 10-15% SDS polyacrylamide gel in IX 
Tris-Glycine Running Buffer at a constant voltage of 150V until the target bands 
were well-resolved. 
2.13.4 Protein transfer to nylon membrane 
Before the protein transfer, a PVDF Immobolin™-P membrane (Millipore) was 
pre-soaked with 70% ethanol and washed with distilled water and finally soaked with 
ice-cold IX transfer buffer [25mM Tris-HCl, 182mM glycine, 20% (v/v) methanol]. 
After SDS-PAGE，the stacking gel was carefully removed from the running gel. 
Filter paper soaked with IX transfer buffer was placed on a semi-dry electroblotter 
(Bio-rad)，then the membrane, the running gel and finally another layer of filter paper. 
The proteins were transferred from the gel to the membrane at a constant voltage of 
14V for 40-50 minutes. 
2.13.5 Antibodies and detection 
After transferring the proteins to a nylon membrane, the membrane was incubated 
with a primary antibody diluted in 5% (w/v) non-fat milk powder in IX PBST [IX 
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PBS, 0.1% (v/v) Tween 20)] at 4°C overnight with slow rotation. 
The primary antibodies included HisG (Invitrogen, 1:5000)，vimentin (Santa Cruz, 
1:200), calnexin (Santa Cruz, 1:200), GAPDH (Trevigen, 1:1000), PCNA 
(Novocastra, 1:500), cyclin D1 (Neomarkers, 1:250), p-catenin (Neomarkers, 1:500), 
histone H3 (Upstate, 1:200) and P-actin (Sigma, 1:6250). 
Following by incubation with a primary antibody, the membrane was washed with 
IX PBST for 10 minutes for 3 times to remove the unbound primary antibody. Then, 
the membrane was incubated with the diluted corresponding secondary antibody 
conjugated horseradish peroxidase (HRP) [anti-mouse (Amersham, 1:1000)， 
anti-rabbit (DAKO, 1:1000)] at room temperature for at least 1 hour with slow 
rotation. Then, the membrane was washed with IX PBST for 10 minutes for 3 times 
to remove the unbound secondary antibody. Finally, the proteins on the membrane 
were detected by Western Lightning® Western Blot Chemiluminescence Reagent 
Plus (Enhanced Liiminol) (PerkinElmer) and the membrane was exposed to a X-ray 
film (Fuji) and developed. 
2.13.6 Stripping membrane 
After the signal detection, the immunoblot was stripped with 20ml Restore Western 
Blotting Stripping Buffer (Pierce) at 37°C for 30 minutes with gentle agitation. Then, 
the membrane was washed with IX PBST briefly for three times and incubated with 
another target primary antibody. 
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2.14 Bromodeoxyuridine proliferation assay 
2.14.1 Bromodeoxyuridine labeling and detection 
Transiently transfected or interferon-treated H9C2 cells in 12-well plates (5x10"^) 
were incubated with 10|jM bromodeoxyridine (BrdU) in DMEM for 14-18 hours, 
with the use of BrdU detection kit III (Roche Ltd.), according to the manufacturer's 
instructions. The cells were first washed with PBS with 10% FBS for 3 times and 
fixed by chilled fixative solution at -20°C for 30 minutes. After that, the cells were 
washed with PBS with 10% FBS for 3 times, then digested by nuclease solution at 
37°C for 30 minutes and subjected to washing for 3 times again. After that, the cells 
were incubated in anti-BrdU-POD at 37°C for 30 minutes and washed 3 times with 
IX washing solution to remove excess antibody, followed by incubation in 
peroxidase substrates in a dark area at room temperature for 5-30 minutes. The 
samples were then transferred from the 12-well plate to a 96-well plate and triplicate 
aliquots from each sample were applied. Extinction of the samples was measured in a 
microtiter plate reader at 405nm with a reference wavelength at 490nm. Background 
BrdU incorporation was subtracted from the samples. Cellular DNA synthesis was 
measured by the BrdU incorporation divided by the respective cell number. 
2.14.2 Cell number determination 
Cells in 12-well plates were trypsinized with 90|al trypsin/EDTA (0.05%/0.5mM) at 
37°C for 20 minutes. Then, 50|al complete medium was added to inactivate the 
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trypsin. The detached cells were dispersed by pipetting up and down and saved in a 
new tube. 50|LI1 of the detached cells was mixed with SO i^l trypan blue exclusion dye 
(Gibco) in a volume ratio of 1:1. Dead cells were stained with trypan blue. Only 
viable cells were counted with the use of a haemocytometer. 
2.15 Fluorescence microscopy 
13x104 cells were seeded on coverlids in 6-well plates. After transient transfection 
for 26-28 hours, the cells were washed with IX PBS and fixed with 3.7% (w/v) 
paraformaldehyde at room temperature for 30 minutes. The cells were washed with 
IX PBS for 3 times. The nuclei were stained by Hoechst 33342 (2.5|ig/ml) 
(Molecular Probes) at room temperature for 10 minutes. The cells were washed with 
IX PBS for 3 times. The cells were mounted with coverlids by glycerol. Images were 
captured by the software Spot Advanced under fluorescence microscope (Nikon 
Eclipse TE2000-U, CTS，Chinetak Scientific). 
2.16 Confocal microscopy 
Cells were seeded, fixed and mounted same as described in the previous section 
(Section 2.15). Images were captured by the software TCS NT (Leica) under 
confocal microscope (Leica TCSNT). 
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2.17 Statistical analysis 
Statistical differences were assessed by one-way ANOVA followed by Levene test 
for homogeneity of variances and post-hoc tests for comparison of individual means. 
A p value ^ 0.05 was considered statistically significant. 
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Chapter 3 
Results 
3.1 Sequence analysis of IFITMl，IFITM2 and 
IFITM3 
3.1.1 Primary structure analysis of rat IFITMl^ 
IFITM2 and IFITM3 
IFITMl, IFITM2 and IFITM3 are located in position 201.1Mb on the rat 
chromosome lq41 according to http://www.ncbi.nlm.nih.gov/. In the rat genome, the 
genes are near to each other. Together with IFITM5 and IFITM6，they have been 
identified on a genomic DNA fragment of less than 70kb of the chromosome 1. The 
rat IFITMl, IFITM2 and IFITM3 encode for proteins of 109，144 and 137 amino 
acids respectively (Table 3.1). 
IFITMl IFITM2 IFITM3 
Number of Amino Acids 109 144 137 
Predicted Molecular 11988 15718.1 14971.3 
Weight 
Table 3.1 Primary Structure Analysis of Rat IFITMl, IFITM2 and IFITM3 by 
the Software ProtParam. 
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3.1.2 Transmembrane helice prediction 
To predict the location and orientation of transmembrane helices in IFITMl, 
IFITM2 and IFITM3, the protein sequences of the three proteins were subjected to a 
transmembrane helice prediction programme, TMHMM V2.0. It is a software 
designed on the basis of a hidden Markov model (Krogh et al.’ 2001; Sonnhammer 
et al., 1998). From the TMHMM results, the topology of the proteins is very similar, 
with two transmembrane helices spanned by outside domains (Figure 3.1; Figure 3.2; 
Figure 3.3). Interestingly, predicted intracellular domain of the proteins is highly 
conserved, with 86% similarity and has two potential phosophorylation sites in 
serine and one in tyrosine (Figure 3.4). 
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TMHMM posterior probabilities for Sequence 
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Figure 3.1 Transmembrane Helice Prediction in Rat EFITMl by the Software 
TMHMM V2.0. 
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TMHMM posterior probabilities for Sequence 
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Figure 3.2 Transmembrane Helice Prediction in Rat IFITM2 by the Software 
TMHMM V2.0. 
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TMHMM posterior probabilities for Sequence 
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Figure 3.3 Transmembrane Helice Prediction in Rat IFITM3 by the Software 
TMHMM V2.0. 
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Gene Gene 
IFITMl MPKEQQEWILGGP_丛mriNM IFITMl 
m i M 2 -MSHNSQAFLPANAGLPP^ IEI：腿XGVTELGEPNNSAWRTTVINM IFITM2 
IFITO MNHTSQAFVNAATGGQPPNIERIKEEXEVSELGAPHGSA釋TTVINM IFIUS 
IFITM PAEI§IPDHVVWSLFNTLFMNFCCLGFIAYSY§VKSRDRKMVGDVTGA IFITMl 
IFITM2 PREV§VPDHVWSLFNTLFFNACaGFIAYAY§VK§RDRKMVGDVIGA IFITM2 
IFITO PREV§VPDHWWSLFNTLFMNFCCLGFIAYAY§VK卿RKMVGWTGA IFITM3 
IFI IM KTYASTAKCLNISSVIFTILMAILTI ILYATKRT IFITMl 
IFnM2 QAYASTAKCU I^SSLIFSVLMVI ICIIIFSTTSAWFQSLSQRTPHSGF IFITM2 
IFITO QAYASTAKCLNISSLVLSILMVIITIVTWI lALNAPRLQT IFITM3 
Figure 3.4 Amino Acid Sequence Comparison Between Rat IFITMl, IFrrM2 
and IFITM3. The sequences in blue represent the intracellular domains predicted 
by TMHMM V2.0. The underlined letter represents the potential phosphorylation 
site predicted by NetPhos2.0. 
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3.1.3 Conserved domain prediction 
The functions of the IFITM family have not been extensively explored. To obtain 
more information about the functions of IFITMl, IFITM2 and IFITM3, we looked 
for the presence of functional motifs by NCBI conserved domain search server. A 
domain named CD225 was located in IFITMl (aa 25-101) (Figure 3.5A), IFITM2 
(aa 40-121) (Figure 3.5B) and IFITM3 (aa 40-103) (Figure 3.5C) and corresponds to 
the human leukocyte antigen. The motif CD225 is associated with interferon 
induced cell growth suppression and also found in a novel hemopoietic cell surface 
protein in differentiating embryonal stem cells (Baird et a!,, 2001). 
A. 
1 2t 4) (I 81 IM 1(6 
B. 
1 2S 50 75 m 125 
c. 
1 26 5* 75 125 137 
Figure 3.5 Domain Search of the Amino Acid Sequence of the Rat IFITM 
Family by the NCBI Conserved Domain Search Server. A domain called CD225 
was predicted in (A) IFITMl (position 25-201), (B) IFITM2 (position 40-121), (C) 
and IFITM3 (position 40-103) and this domain was related to interferon cell growth 
suppression. 
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3.1.4 Sequence alignment across different 
species 
The nucleotide and amino acid sequences of rat IFITMl, IFITM2 and IFITM3 were 
aligned with bovines, mice and humans. In terms of the DNA or protein level, these 
genes are highly conserved in rats, bovines, mice and humans (Table 3.2). 
Organism Identity (%) 
Rat IFITMl Rat IFITM2 Rat IFITM3 “ 
DNA Protein DNA Protein DNA Protein 
Bovine ^ 56 - - 83 68 
Mouse 81 94 93 97. 89 
Human 68 61 71 62 83 72 
Table 3.2 DNA and Protein Sequence Alignments for Rat IFITMl, IFITM2 and 
IFITM3 with Other Species. 
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3.2 Differential expression of IFITMl，IFITM2 
and IFITM3 during rat myocardial 
development 
The expression profiles of IFITMl, IFITM2 and IFITM3 during myocardial 
development were first studied in postnatal 1-day-old, 7-day-old, 14-day-old and 
3-month-old Sprague Dawley rat ventricular myocardium. From the real-time PGR 
results, mRNA level of IFITMl increased steadily from 1-day-old to 14-day-old 
myocardium, but a 11-fold increase was observed in 3-month old rat ventricular 
myocardium. On the contrary, IFITM2 and IFITM3 showed a different expression 
pattern. Their mRNA levels increased drastically by 7-folds in 14-day-old rat 
ventricles, but then slightly dropped in the adult myocardium (Figure 3.6). The 
differential expression pattern of IFITMl, IFITM2 and IFITM3 implies that they are 
developmentally regulated during postnatal myocardial development. 
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Figure 3.6 Expression Profiles of IFITMl, IFITM2 and IFITM3 in 1-Day, 
7-Day, 14-Day and 3-Month-old SD Rat Ventricular Myocardium by Real-time 
PCR. p-actin acted as the internal control for the normalization of cDNA templates. 
Filled bars indicate the means and T bars indicate the standard errors of the means 
for three separate experiments with triplicates. The expression levels were presented 
in relative arbitrary units. */7^0.05 versus control. 
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3.3 Altered mRNA levels of IFITMl，IFITM2 
and IFITM3 during differentiation of 
H9C2 cells 
H9C2 is a rat myoblast cell line derived from embryonic heart tissue. To study the 
expression profiles of IFITMl, IFITM2 and IFITM3 in H9C2 cells, the cells were 
first induced to differentiate by DMEM with 1.5% HS for 2，4, 6 and 8 days to 
mimic the differentiation status during heart development. The morphology of the 
H9C2 cells was changed during differentiation. After differentiating for 4 days, the 
cells became more elongated. From the sixth day of differentiation onwards, the 
cells became multinucleated and myotubes were observed under a light microscope. 
On the eighth day, extensive networks of myotubes were found (Figure 3.7). 
To monitor the differentiation status of H9C2 cells, the expression of a cardiac 
differentiation marker, myosin light chain ventricular isoform 2 (MLC-2V) was also 
studied. By real-time PCR, MLC-2V mRNA level was shown to augment for more 
than 2 folds after differentiating for 8 days, compared to that of the undifferentiated 
cells (Figure 3.8). The increase in MLC-2V mRNA expressions further confirmed 
the induction of differentiation of H9C2 cells by low serum medium. 
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Figure 3.7 Analysis of Morphological Changes of H9C2 Cells during 
DifTerentiation. The H9C2 cells were induced to differentiate by 1.5% HS for 8 
days. The formation of myotubes was observed under light microscope. 
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Figure 3.8 Expression Profile of MLC-2V during Differentiation of H9C2 Cells 
by Real-time PCR. The H9C2 cells were induced to differentiate by 1.5% HS for 8 
determined days. The upregulation of the cardiac differentiation marker, MLC-2V 
confirmed the promotion of differentiation in H9C2 cells, p-actin acted as the 
internal control for normalization of cDNA templates. Filled bars indicate the means 
and T bars indicate the standard errors of the means for three separate experiments 
with triplicates. The expression levels were presented in relative arbitrary units. *p 
^0.05 versus control. 
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Similarly, from the real-time PCR results, there was an upregulation of IFITMl, 
IFITM2 and IFITM3 during differentiation of H9C2 cells. IFITMl and IFITM3 
mRNA expression levels continuously increased up to day 8 for more than 3 folds 
and 5 folds respectively, when compared to the undifferentiated H9C2 cells. On the 
other hand, IFITM2 mRNA expression level peaked at day 6 with a 2.5-fold increase 
and remained fairly constant afterwards (Figure 3.9). The change in the mRNA 
expression pattern of IFITMl, IFITM2 and IFITM3 is another evidence to further 
support that they may be involved in differentiation of myoblasts. 
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Figure 3.9 Expression Profiles of IFITMl, IFITM� and IFITM3 during 
Differentiation of H9C2 Cells by Real-time PCR. The H9C2 cells were induced to 
differentiate by 1.5% HS for 8 days. GAPDH acted as the internal control for 
normalization of cDNA templates. Filled bars indicate the means and T bars indicate the stand rd errors of the eans for three separate experiments with triplicates. Thexpression levels were pr sented in re ative arbitrary units. */7^0.05 versus control. 
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3.4. Cloning of IFITMl, IFITM2 and IFITM3 
To further study the role and localization of IFITMl，IFITM2 and IFITM3 in H9C2 
cells, the rat full-length IFITMl, IFITM2 and IFITM3 were amplified and cloned in 
the mammalian expression vector pcDNA4. The size of the amplified PGR 
fragments of IFITMl, IFITM2 and IFITM3 was 330bp, 435bp and 414bp 
respectively. 
IFITM1 IFITM2 IFITM3 Size (bp) • • • 
^^^^Sm ^ ^ ^ ^ H H I — 2 0 0 0 
• • 睡 
Figure 3.10 Amplified PGR Fragments of the IFITM Family after DNA 
Electrophoresis on an Agarose Gel. The size of the amplified PGR fragments for 
cloning into the pcDNA4 vector was 330bp (IFITMl), 435bp (IFITM2) and 414bp 
(IFITM3). 
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3.5 Subcellular localization of IFITMl, IFITM2 
and IFITM3 
3.5.1 Fluorescence microscopy 
The analysis of the predicted IFITMl, IFITM2 and IFITM3 suggests that the 
presence of two putative transmembrane domains. To investigate the cellular 
localization of IFITMl, IFITM2 and IFITM3, the full-length sequences of the genes 
were first cloned into the pcDNA4 vector and transiently transfected into H9C2 rat 
heart myoblasts. Probably owing to the poor specificity of the primary antibody, the 
immunostaining results were not satisfactory (data not shown). 
Considering the small size of the IFITMl, IFITM2 and IFITM3 proteins (predicted 
size: 12-16kDa), they are able to pass through the nuclear membrane freely. 
Therefore, we decided to clone the genes into the pEGFP-Cl and pEGFP-Nl vectors 
and transfected the constructs into H9C2 cells for 26-28 hours. As shown by 
fluorescence microscope, the IFITM, IFITM2 and IFITM3 GFP fusion proteins were 
detected as distinct, punctuate and vesicle-like distribution, most densely clustered 
in the perinuclear space and also localized in the cytoplasm with lower expression. 
In addition, the nucleus did not have any significant staining (Figure 3.11; Figure 
3.12). This microscopic localization is suggestive of membrane-association of 
IFITMl, IFITM2 and IFITM3. Experiments using fluorescence confocal microscopy 
showed identical localization patterns (Figures 3.13-3.18) and excluded the 
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• • • • • • • • • • • • 
Figure 3.13 Series 夏mages Showing 12 Layers of IFITMl-GFP-Cl (A-L) from 
-5|im to -lO^m by Confocal Microscopy 
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• • • • • • • • • • • • 
Figure 3.14 Series 夏mages Showing 12 Layers of IFITMl-GFP-Nl (A-L) from 
-18.5^m to -24^m by Confocal Microscopy 
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• • • • • • • • • • • • 
Figure 3.15 Series Images Showing 12 Consecutive Layers of IFITM2-GFP-C1 
(A-L) from -7nm to -ll.Sfim by Confoca里 Microscopy 
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• • • • • • • • • • • • 
Figure 3.16 Series Images Showing 12 Consecutive Layers of IFITM2-GFP-N1 
(A-L) from -lOjum to -15^m by Confocal Microscopy 
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• • • • • • • • • 
Figure 3.17 Series Images Showing 12 Consecutive Layers of IFITM3-GFP-C1 
(A-L) from -8fim to by Confocal Microscopy 
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• • • • • • • • • • • • 
Figure 3.18 Series 夏mages Showing 12 Consecutive Layers of IFITM3-GFP-N1 
(A-L) from -22fun to -26^m by Confocal Microscopy 
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3.5.2 Subcellular fractionation 
To further confirm the location of IFITMl, IFITM2 and IFITM3 fusion proteins, the 
cell homogenates were separated into 4 fractions according to their subcellular 
localization. The constructs of IFITM l-pcDNA4, IFITM2-pcDNA4 and 
IFITM3-pcDNA4 were transfected into H9C2 cells for 26-28 hours. The transfected 
cells were harvested and lysed in different extraction buffers. By Western blot 
analysis, IFITMl, IFITM2 and IFITM3 were predominately localized in the 
membrane and organelle fraction. Moreover, a small amount of IFITMl and IFITM3 
proteins were detectable in the cytoplasmic fraction and a trace amount of IFITM2 
protein was detected in the nuclear fraction. The results of subcellular fractionation 
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Figure 3.19 Localization of IFITM, IFITM2 and IFITM3 in H9C2 Cells by 
Subcellular Fractionation Analysis. IFITMl, IFITM2 and IFITM3 were 
predominately detected in the membrane and organelle fraction. GAPDH (cytosol), 
calnexin (membrane and organelle), histone H3 (nucleus) and vimentin 
(cytoskeleton) were the marker proteins for each fraction. The experiment was 
performed for two times. 
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3.6 In vitro induction by interferons-a, p and y 
in H9C2 cells 
IFITM 1，IFITM2 and IFITM3 have been previously analyzed in detail (Reid et al., 
1989). They have been shown to belong to a group of interferon-inducible genes, 
having an interferon-stimulated response element (ISRE) or gamma-activating 
sequence (GAS) in the 5' flanking promoter/enhancer region. ISRE confers 
responsiveness to either predominately type I interferons, for example, for the 6-16 
gene (Kelly et al.’ 1985; Porter et al., 1988) and the ISG 15 and 54 genes (Lamer et 
al., 1984; Levy et al., 1988), or to type I and type II interferons, like the 2-5A 
synthetase gene and the major histocompatibility complex class I genes (Kelly et al., 
1985; Luster et al., 1985; Fan et al., 1988; Newburger et al.，1988). On the other 
hand, GAS confers to responsiveness to interferon-y (Decker at al., 1991). However, 
- the induction of the IFITM genes has not been investigated in cardiac cells. Because 
of this reason, we treated H9C2 cells with different concentrations of interferons-a, 
p and Y and then studied whether IFITMl, IFITM2 and IFITM3 were induced upon 
the interferon treatment in H9C2 cells. 
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3.6.1 Upregulation of IFITMl and IFITM3 upon 
interferon-a treatments 
H9C2 cells were treated with interferon-a of concentrations of lOOU/ml，200U/ml 
and 500U/ml for 24 hours. The mRNA expressions of IFITMl, IFITM2 and IFITM3 
in interferon-a treated H9C2 cells were then assessed by quantitative real-time PCR 
with reference to the untreated control. In Figure 3.20, interferon-a gave a boost to 
the expression of IFITM3 in H9C2 cells and the upregulation of IFITM3 even 
reached more than 40 folds at the concentration of 500U/ml. For IFITMl, the 
expression did not change significantly under lower concentrations of interferon-a, 
but it was upregulated at a higher concentration and showed a 8-fold increase upon 
the treatment of 500U/ml interferon-a. In contrast, IFITM2 did not respond to 
interferon-a and the mRNA expression did not alter considerably in various 
concentrations of interferon-a. 
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Figure 3.20 Expression Levels of IFITMl, IFITM2 and IF1TM3 under 
Different Concentrations of Interferon-a Treatment for 24 Hours by Real-time 
PCR H9C2 cells were treated with interferon-a with concentrations of lOOU/ml, 
200U/ml and 500U/ml. GAPDH acted as the internal control for normalization of 
cDNA templates. Filled bars indicate the means and T bars indicate the standard 
errors of the means for three separate experiments with triplicates. The expression 
levels were presented in relative arbitrary units. */>^0.05 versus control. 
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3.6.2 Increase in IFITMl and IFITM3 
expression upon interferon-/} treatments 
H9C2 cells were treated with interferon-p of concentrations of lOOU/ml, 200U/ml 
and 500U/ml for 24 hours in the same way. From the real-time PGR results, IFITMl 
and IFITM3 were upregulated in response to the interferon-(3 treatments. IFITMl 
mRNA expression increased for 5 folds at lOOU/ml and maximally for 8 folds at 
500U/mL For IFITM3, a significant upregulation was observed, with a more than 
40-fold increase in the presence of lOOU/ml and 200U/ml interferon-p and peaked at 
200U/ml interferon-p. Unexpectedly, IFITM3 expression did not continue to 
increase at a higher concentration of interferon-p. Instead, the expression decreased 
slightly at 500U/ml interferon-p. Thus, 200U/ml interferon-P was the optimal dose 
to induce the maximum amount of IFITM3. On the other hand, IFITM2 was 
non-responsive to interferon-P, even if the concentration was increased up to 
500U/ml (Figure 3.21). 
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Figure 3.21 Expression Levels of IFITMl, IFITM2 and IFITM3 under 
Different Concentrations of Interferon-p Treatment for 24 Hours by Real-time 
PCR. H9C2 cells were treated with interferon-P with concentrations of lOOU/ml, 
200U/ml and 500U/ml. GAPDH acted as the internal control for normalization of 
cDNA templates. Filled bars indicate the means and T bars indicate the standard 
errors of the means for three separate experiments with triplicates. The expression 
levels were presented in relative arbitrary units. *p^0.05 versus control. 
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3.6.3 Induction of IFITMl upon interferon-y 
treatments 
When treating H9C2 cells with interferon-y of 10r|g/ml, 20r|g/ml and 40r|g/ml for 24 
hours, interferon-y showed a different induction pattern of the IFITM gene family. 
The results of real-time PGR demonstrated that IFITMl was notably induced by 
interferon-y for at least 11 folds under the concentrations of 10r|g/ml, 20r|g/ml and 
40r|g/ml and maximally for 21 folds upon the 40T|g/ml interferon-y treatment. A 
dose-dependent effect of interferon-y on IFITMl expression was shown, with a 
continuous increase of the IFITMl expression after interferon-y stimulation with the 
concentrations from 10r|g/ml to 40r|g/ml. However, the expression of IFITM2 and 
IFITM3 did not alter significantly in the presence of interferon-y (Figure 3.22). 
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Figure 3.22 Expression Levels of IFITMl, IFITM2 and IFITM3 under 
Different Concentrations of Interferon-y Treatment for 24 Hours by Real-time 
PCR. H9C2 cells were treated with interferon-y with concentrations of lOtig/ml, 
20T|g/ml and 40iig/ml. GAPDH acted as the internal control for normalization of 
cDNA templates. Filled bars indicate the means and T bars indicate the standard 
errors of the means for three separate experiments with triplicates. The expression 
levels were presented in relative arbitrary units. *p^0.05 versus control. 
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3.7 DNA synthesis after in vitro induction of 
interferons-a, p and y in H9C2 cells 
Interferons play an important role in the control of cell growth. They are known to 
induce tumor suppressor genes and directly inhibit cell proliferation (Pfeffer et al, 
1998). Therefore, we were interested in investigating whether interferons would 
reduce cellular DNA synthesis in H9C2 cells. H9C2 cells were first treated with 
interferon-a, p or y for 24 hours and then labeled with BrdU for 14-18 hours. BrdU, 
an analog of uridine, would incorporate into DNA during DNA synthesis. Therefore, 
cellular DNA synthesis was measured by the BrdU incorporation divided by the 
respective cell number and presented in percentage relative to the untreated cells. 
3.7.1 Decrease in DNA synthesis by interferon-a 
treatments 
H9C2 cells were grown in the presence of lOOU/ml, 200/ml or 500U/ml interferon-a 
for 24 hours. Figure 3.23 showed that the relative BrdU uptakes in H9C2 cells 
decreased after the treatments of interferon-a. There was a significant reduction in 
the relative BrdU incorporation of 66%, 57% and 49% under lOOU/ml, 200U/ml and 
500U/ml interferon-a respectively, when compared to the untreated control. This 
demonstrated that interferon-a reduced cellular DNA synthesis in H9C2 cells. At the 
same time, in the presence of interferon-a, the cell number was remarkably 
decreased in a dose-dependent manner, compared to the untreated control (Figure 
3.24). 
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Figure 3.23 DNA Synthesis Measured by BrdU Incorporation after Interferon-a 
Treatment for 24 Hours. H9C2 cells were treated with interferon-a with 
concentrations of lOOU/ml, 200U/ml and 500U/ml. The relative BrdU uptakes of the 
samples were divided by the respective cell number and presented in percentage, 
relative to the BrdU uptake of the untreated cells. Filled bars indicate the means and 
T bars indicate the standard errors of the means for three separate experiments with 
triplicates. */?^0.05 versus control. 
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Figure 3.24 Cell Number Counted by a Hematocytometer before and after the 
Interferon-a Treatment for 24 Hours. H9C2 cells were treated with interferon-a 
with concentrations of lOOU/ml, 200U/ml and 500U/ml. The cell number of each 
sample was presented in percentage, relative to the cell number counted before the 
treatment. Filled bars indicate the means and T bars indicate the standard errors of 
the means for three separate experiments. versus the untreated control 
before the treatment. 
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3.7.2 Reduction in DNA synthesis by interfewn-p 
treatments 
On the other hand, H9C2 cells were treated with interferon-p with concentrations of 
lOOU/ml, 200U/ml and 500U/ml for 24 hours. Figure 3.25 showed that when treated 
with interferon-p, the relative BrdU uptakes were reduced compared to that of the 
untreated control. There was a decrease of 47%, 48% and 15% in the BrdU 
incorporation at lOOU/ml, 200U/ml and 500U/ml interferon-p respectively. 
Therefore, interferon-p exhibited inhibition of DNA synthesis in H9C2 cells. In 
parallel, as shown by trypan blue exclusion assay, when compared to the untreated 
control, the cell number was greatly reduced in a dose-dependent fashion in the 
response to interferon-p (Figure 3.26). 
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Figure 3.25 DNA Synthesis Measured by BrdU Incorporation after Interferon-p 
Treatment for 24 Hours. H9C2 cells were treated with interferon-P with 
concentrations of lOOU/ml, 200U/ml and 500U/ml. The relative BrdU uptakes of the 
samples were divided by the respective cell number and presented in percentage, 
relative to the BrdU uptake of the untreated cells. Filled bars indicate the means and 
T bars indicate the standard errors of the means for three separate experiments with 
triplicates. */7^0.05 versus control. 
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Figure 3.26 Cell Number Counted by a Hematocytometer before and after the 
Interferon-p Treatment for 24 Hours. H9C2 cells were treated with interferon-P 
with concentrations of lOOU/ml, 200U/ml and 500U/ml. The cell number of each 
sample was presented in percentage, relative to the cell number counted before the 
treatment. Filled bars indicate the means and T bars indicate the standard errors of 
the means for three separate experiments. VS0 .05 versus control. 
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3.7.3 A slight increase in DNA synthesis by 
interferon-y treatment 
In the same way, H9C2 cells were incubated in 10r|g/ml, 20r|g/ml and 40r|g/ml 
interferon-Y for 24 hours. Interferons are known to confer an antiproliferative 
activity and cellular DNA synthesis was supposed to reduce in the presence of 
interferon-y. Surprisingly, there was a significant increase of 38% and 42% in 
relative BrdU uptakes at 20r|g/ml and 40r|g/ml respectively. However, the relative 
BrdU incorporation did not change significantly when H9C2 cells were treated with 
10r|g/ml interferon-Y (Figure 3.27). This demonstrated that only a higher 
concentration of interferon-y could promote cellular DNA synthesis in H9C2 cells. 
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Figure 3.27 DNA Synthesis Measured by BrdU Incorporation after Interferon-^ 
Treatment for 24 Hours. H9C2 cells were treated with interferon-y with 
concentrations of lOrjg/ml, 20Tig/ml and 40Tig/ml. The relative BrdU uptakes of the 
samples were divided by the respective cell number and presented in percentage, 
relative to the BrdU uptake of the untreated cells. Filled bars indicate the means and 
T bars indicate the standard errors of the means for three separate experiments with 
triplicates. */7^0.05 versus control. 
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3.8 Proliferating cell nuclear antigen 
expression after in vitro induction of 
interferons-a, p and y in H9C2 cells 
Proliferating cell nuclear antigen (PCNA), which is a component of the DNA 
replication fork, provides processivity for DNA polymerases during DNA replication 
and essential in DNA synthesis (Prelich et al, 1982). Therefore, after measuring the 
BrdU incorporation, we studied the PCNA expression by real-time PCR and Western 
blotting after the interferon-a, p and y treatments in H9C2 cells and this provided us 
another evidence of the alteration in the rate of DNA synthesis. 
3.8.1 Reduction in PCNA expression by 
interferon-a treatments 
After treating H9C2 cells with lOOU/ml, 200U/ml and 500U/ml interferon-a for 24 
hours, PCNA expression was studied by real-time PCR and Western blotting. From 
the results of real-time PCR, interferon-a decreased PCNA mRNA expression by 2.5 
folds, 3 folds and nearly 5 folds at lOOU/ml, 200U/ml and 500U/ml respectively 
relative to the untreated cells (Figure 3.28A). Consistent with the real-time PCR 
results, there was a dose-dependent drop in the PCNA protein level as revealed by 
Western blot analysis (Figure 3.28B). Taken together, as shown by the drop in 
relative BrdU uptake and downregulation of PCNA in terms of mRNA and protein 
levels, interferon-a reduced DNA synthesis in H9C2 cells. 
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Figure 3.28 Expression Levels of PCNA after Interferon-a Treatment for 24 
Hours in H9C2 Cells. H9C2 cells were treated with interferon-a with 
concentrations of 1 OOU/ml, 200U/ml and 550U/ml. (A) mRNA expression analyzed 
by real-time PCR. GAPDH acted as the internal control for normalization of cDNA 
templates. Filled bars indicate the means and T bars indicate the standard errors of 
the means for three separate experiments with triplicates. The expression levels were 
presented in relative arbitrary units. */7^0.05 versus control, (b) Protein expression 
analyzed by Western blot analysis, p-actin acted as the internal control for normalization of protein loading. The ex eriment was repeated for 3 times. 
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3.8.2 Downregulation of PCNA by interferon-/} 
treatments 
Real-time PCR analysis showed that the PCNA mRNA expression dropped in H9C2 
cells in the presence of interferon-|3. After the interferon-p treatments, PCNA mRNA 
expression levels were reduced by 2.5 folds, 3 folds and 3.5 folds at lOOU/ml， 
200U/ml and 500U/ml respectively (Figure 3.29A). On the other hand, Western blot 
analysis showed that the PCNA protein level was decreased maximally in response 
to lOOU/ml interferon-p and the reduction of the PCNA expression was not in a 
dose-dependent fashion (Figure 3.29B). 
Because of the decrease in the relative BrdU incorporation and downregulation of 
PCNA on the mRNA and protein levels upon the interferon-p stimulation, 
interferon-p was demonstrated to inhibit DNA synthesis in H9C2 cells. 
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Figure 3.29 Expression Levels of PCNA after Interferon-^ Treatment for 24 
Hours in H9C2 Cells. H9C2 cells were treated with interferon-p with 
concentrations of lOOU/ml, 200U/ml and 550U/ml. (A) mRNA expression analyzed 
by real-time PCR. GAPDH acted as the internal control for normalization of cDNA 
templates. Filled bars indicate the means and T bars indicate the standard errors of 
the means for three separate experiments with triplicates. The expression levels were 
presented in relative arbitrary units. *p^0.05 versus control. (B) Protein expression 
analyzed by Western blot analysis, p-actin acted as the internal control for 
normalization of protein loading. The experiment was repeated for 3 times. 
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3.8.3 PCNA expression not significantly affected 
by interferon-y treatments 
We treated H9C2 cells with 10r|g/ml, 20Tig/ml and 40rig/ml interferon-y for 24 hours 
and then assessed the mRNA expression of PCNA. Real-time PCR results 
demonstrated that the mRNA expression of PCNA did not change considerably, with 
a less than 2-fold increase in the mRNA level from 10r|g/ml to 40r|g/ml interferon-y 
exposure (Figure 3.30A). In consistent with this, Western blot analysis showed that 
the protein expression of PCNA was slightly increased under 20r|g/ml, 40r|g/ml and 
100r|g/ml interferon-y, but the upregulation of the PCNA protein level was not 
significant (Figure 3.30B). 
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Figure 3.30 Expression Levels of PCNA after Treatments of Interferon-y for 24 
Hours in H9C2 Cells. H9C2 cells were treated with interferon-y with 
concentrations of 1 OT|g/ml, 20Tig/ml, 40Tig/ml and 100T|g/ml. (A) mRNA expression 
analyzed by real-time PCR. GAPDH acted as the internal control for normalization 
of cDNA templates. Filled bars indicate the means and T bars indicate the standard 
errors of the means for three separate experiments with triplicates. The expression 
levels were presented in relative arbitrary units. */7^0.05 versus control. (B) Protein 
expression analyzed by Western blot analysis, p-actin acted as the internal control 
for normalization of protein loading. The experiment was repeated for 3 times. 
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3.9 Effect of overexpression of IFITMl, 
IFITM2 and IFITM3 on DNA synthesis in 
H9C2 cells 
In the previous sections, we demonstrated that interferons induced the mRNA 
expression of the IFITM gene family and interferons-a and p inhibited cellular DNA 
synthesis in H9C2 cells. Evidence has showed that the IFITM gene family correlates 
with cellular proliferation (Bradbury et al, 1993; Deblandre et al, 1995) and plays a 
role in cell cycle control (Evans et al, 1990; Huang et al, 2000; Brem et al, 2001; 
Certa et al., 2001). Therefore, we addressed the hypothesis and asked whether 
overexpression of IFITMl, IFITM2 and IFITM3 would alter the rate of DNA 
synthesis in H9C2 cells. 
H9C2 cells were transiently transfected with IFITM l-pcDNA4, IFITM2-pcDNA4 
and IFITM3-pcDNA4 for 26-28 hours and then labeled with BrdU for 14-18 hours. 
The transfection efficiency was about 20%-30% (data not shown). Cellular DNA 
synthesis was measured by the BrdU incorporation divided by the respective cell 
number. By comparing to the BrdU uptake of the empty vector pcDNA4, 
overexpression of IFITMl resulted in a slight decrease in BrdU incorporation of 
12% in H9C2 cells. On the other hand, transient transfection of IFITM2 and IFITM3 
did not alter the BrdU uptakes significantly (Figure 3.31). This demonstrated that 
overexpression of IFITMl inhibited DNA synthesis in H9C2 cells, but IFITM2 and 
IFITM3 did not exert any significant changes on DNA synthesis in H9C2 cells. 
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Figure 3.31 DNA Synthesis Measured by BrdU Incorporation after 
Overexpression of IFITM l-pcDNA4, IFITM2-pcDNA4 and IFITM3-pcDNA4 
for 26-28 Hours. The relative BrdU uptakes of the samples were divided by the 
respective cell number and presented in percentage, relative to the BrdU uptake of 
the empty vector pcDNA4. Filled bars indicate the means and T bars indicate the 
standard errors of the means for three separate experiments with triplicates. * p ^ 
0.05 versus control. 
94 
Chapter 3: Results 
3.10 Proliferating cell nuclear antigen 
expression after overexpression of 
IFITMl，IFITM2 and IFITM3 in H9C2 
cells 
Because PCNA is essential in DNA synthesis, we studied the expression ofPCNA as 
another evidence of the alteration in the rate of DNA synthesis. H9C2 cells were 
transfected with IFITMl-pcDNA4, IFITM2-pcDNA4 and IFITM3-pcDNA4 for 
26-28 hours. Western blot analysis revealed that PCNA was slightly downregulated 
in IFITM 1 -pcDNA4-transfected H9C2 cells, but the protein expression of PCNA did 
not change considerably in IFITM2-pcDNA4- and IFITM3-pcDNA4-transfected 
H9C2 cells, when compared to the empty vector pcDNA4-transfected cells (Figure 
3.32). This result is consistent with the findings in the BrdU proliferation assay, in 
which transiently transfecting IFITM l-pcDNA4 decreased DNA synthesis in H9C2 
cells to some extent. 
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Figure 3.32 Protein Expression of PCNA after Overexpression of 
IFITlVIl-pcDNA4，IFITM2-pcDNA4 and IFITM3-pcDNA4 in H9C2 Cells for 
26-28 Hours Determined by Western Blot Analysis, p-actin acted as the internal 
control for normalization of protein loading. The experiment was repeated for 3 
times. 
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3.11 p-catenin and cyclin D1 expression after in 
vitro induction of interferons-a, p and y in 
H9C2 cells 
P-catenin is the central and essential component in the Wnt signaling cascade. 
Evidence has shown that the IFITM family is activated upon the activation of Wnt 
signaling and seems to be a good candidate target gene of the Wnt pathway in 
colorectal cancers (Andreu et al, 2006). From our previous results, interferons 
induced the expression of IFITMl, IFITM2 and IFITM3 in H9C2 cells. Therefore, 
we first asked whether the expression of p-catenin and cyclin Dl, one of the 
Wnt/p-catenin target genes，would be altered in the presence of interferons. 
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3.11.1 Downregulation of p-catenin and cyclin 
D1 by interferon-a 
H9C2 cells were exposed to 1 OOU/ml, 200U/ml and 500U/ml interferon-a for 24 
hours. From the results of Western blot analysis, the protein levels of p-catenin and 
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Figure 3.33 Expression of p-catenin and Cyclin Dl after Interferon-a Treatment 
for 24 Hours in H9C2 Cells Determined by Western Blot Analysis. H9C2 cells 
were treated with interferon-a with concentrations of 1 OOU/ml, 200U/ml and 
500U/ml. P-actin acted as the internal control for normalization of protein loading. 
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31L2 Decrease in p-catenin and cyclin Dl 
expression by interferon-p 
After treating H9C2 cells with interferon-p with concentrations of lOOU/ml, 
200U/ml and 500U/ml for 24 hours, the protein levels of p-catenin and cyclin Dl 
were examined. Western blot analysis revealed that p-catenin and cyclin Dl were 
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Figure 3.34 Expression of p-catenin and Cyclin Dl after Interferon-p 
Treatment for 24 Hours in H9C2 Cells Determined by Western Blot Analysis. 
H9C2 cells were treated by interferon-p with concentrations of lOOU/ml, 200U/ml 
and 500U/mI. p-actin acted as the internal control for normalization of protein 
loading. 
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3.11.3 Reduction of p-catenin and cyclin D1 
expression by interferon-y 
Upon the treatments of interferon-丫 of lOrig/ml, 20Tig/ml, 40T|g/ml and 100r|g/ml for 
24 hours, the protein expression of p-catenin and cyclin D1 was notably decreased, 
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Figure 3.35 Expression of p-catenin and Cyclin D1 after Interferon-y Treatment 
for 24 Hours in H9C2 Cells Determined by Western Blot Analysis. H9C2 cells 
were treated with interferon-y with concentrations of 10T|g/ml, 20T|g/ml, 40T|g/ml 
and 100T|g/ml. p-actin acted as the internal control for normalization of protein 
loading. 
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3.12 p-catenin and cyclin D1 expression after 
overexpression of IFITMl，IFITM2 and 
IFITM3 in H9C2 cells 
Since interferons-a, p and y reduced p-catenin and cyclin D1 protein levels, we 
would hypothesize that the IFITM gene family correlated with the Wnt/p-catenin 
signaling pathway. To test this hypothesis, we transiently transfected 
IFITM l-pcDNA4, IFITM2-pcDNA4 and IFITM3-pcDNA4 into H9C2 cells for 
26-28 hours and then studied the protein expressions of p-catenin and cyclin D1 by 
Western blot analysis. 
From the results, the protein level of P-catenin was significantly reduced in 
IFTIMl-pcDNA4 and IFITM3-pcDNA4-transfected cells and slightly decreased in 
IFITM2-pcDNA4-transfected cells. On the other hand, cyclin D1 protein expression 
did not change significantly when transfected with IFITM l-pcDNA4, 
IFITM2-pcDNA4 and IFITM3-pcDNA4 (Figure 3.36). 
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Figure 3.36 Expression of p-catenin and Cyclin D1 after Overexpression of 
IFITMl-pcDNA4, IFITM2-pcDNA4 and IFITM3-pcDNA4 in H9C2 Cells for 
26-28 Hours Determined by Western Blot Analysis, p-actin acted as the internal 
control for normalization of protein loading. 
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Chapter 4 
Discussion 
4.1 Upregulation of IFITMl，IFITM2 and 
IFITM3 during myocardial development 
IFITMl, a member of an interferon-inducible gene family, was first isolated by 
differential screening in a cDNA library of interferon-p treated human Daudi cells 
(Blomstrom et al., 1988). IFITMl encodes a leukocyte antigen, Leu-13 that is part of 
a membrane complex of proteins involved in the transduction of antiproliferative 
signals (Evans et al., 1990; Takahashi et al, 1990; Bradbury et al., 1992; Bradbury et 
al, 1993). Soon after, the expression of another family member, IFITM3, has also 
been correlated with cell cycle arrest and inhibition of tumor cell growth (Hillamn et 
al., 1987; Huang et al” 2000; Brem et al,, 2001; Brem et al, 2003). 
An additional property of IFITM family proteins is their involvement in mediating 
adhesion in connection with normal cellular processes. IFITMl and IFITM3 results 
in homotypic adhesion of B and T cells and cell-cell contact formation during the 
development of mammary gland respectively (Evans et al, 1993; Deblandre et al., 
1995; Zucchi et al, 1998). IFITMl, IFITM2 and IFITM3 in germ cells are 
apparently important during embryogenesis and the development of primary tissues 
in mice. Their expression marks the onset of germ cell competence and may 
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contribute to mediating interactions amongst germ cells and their surrounding 
neighbors (Saitou et al” 2002; Lange et al., 2003). 
The proliferative capability of rat cardiomyocytes still retains from postnatal 1 to 3 
days (Li et al., 1996), during which low mRNA expressions of IFITMl, IFITM2 and 
IFITM3 were detected. Thereafter, from 6 to 14 days of age, a transitional phase 
from hyperplasia to hypertrophy occurs and this rapid switch is critical for the 
molecular events behind terminal differentiation and the loss of proliferative ability 
in cardiomyocytes to take place (Clubb and Bishop, 1984; Clubb et al, 1987). In 
agreement with the timing of the rapid switch, our results demonstrated a continuous 
increase in the expressions of IFITMl from postnatal 7 days and IFITM2 and 
IFITM3 from postnatal 14 days in rat ventricles. The result is consistent with the 
differential expression of IFITMl in fetal and adult heart tissues (Anisimov et al., 
2000). 
Taken together, the upregulation of IFITMl, IFITM2 and IFITM3 during myocardial 
development and their antiproliferative and cell adhesion properties in various cell 
lines suggest that the proteins are potentially involved in terminal differentiation and 
cell proliferation during heart development. 
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4.2 Subcellular localization of IFITMl, IFITM2 
and IFITM3 
Bioinformatics analysis of the primary structures of IFITMl, IFITM2 and IFITM3 
suggests that they are membrane proteins. They have two putative transmembrane 
regions，with the amino and carboxy terminus ends located on the same side of the 
membrane. The intracellular domain consists of three potential phosphorylation sites， 
suggesting a possible phosphorylation/dephosphorylation domain. The predicted 
structures of the three IFITM proteins resemble a receptor, which will be clarified by 
further investigations. 
Experimental data obtained by fluorescence confocal microscopy after transfection 
of the GFP fusion proteins and subcellular fractionation after overexpression of the 
pcDNA4 recombinant constructs into H9C2 cardiomyoblast cells support the 
membrane association of IFITMl, IFITM2 and IFITM3. Although we failed to find 
the recombinant proteins in the plasma membrane under our experimental conditions, 
the same vesicle-like distributions were also reported in the gene localization studies 
of IP 15 (mouse homologue of IFITM3) in Cos? cells (Ropolo et a!., 2004) and 1-8U 
(human homologue of IFITM3) in DIO melanoma cells (Brem et al., 2003). In 
addition, as shown by the subcellular fractionation analysis, a trace amount of 
IFITM2 was detected in the nuclear fraction and it might be the contaminant during 
extraction of the protein from different subcellular compartments. 
Interestingly, Brem et al. examined the localization of 1-8U in more detail by 
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immunoelectron microscopy and detected the protein in multivesicular compartments 
that contained exosome-like organelles (Brem et al, 2003). Exosomes are small 
membrane vesicles formed by inward budding of multivesicular compartment 
membranes. These multivesicular bodies may then fuse with the lysosome, resulting 
in mRNA and protein degradation (Van Hoof and Parker, 1999)，or alternatively fuse 
with the plasma membrane, releasing the small vesicles into the extracellular space 
(Stoorvogel et al, 2002; Thery et al” 2002). Exosomes occur in many cell types, 
including various tumors (Wolfers et al” 2001), intestinal cells (Lin et al, 2005), 
epididymis cells (Sullivan et al, 2005), dentritic cells (Zitvogel et al,, 1998), kidney 
cells (Pisitkun et al., 2004), reticulocytes (Pan and Johnstone, 1983; Pan et al, 1985; 
Johnstone, 2005) and antigen-presenting cells such as mast and B cells (Raposo et al” 
1996; Raposo et al., 1997). Depending on the cell type, exosomes contain a variety 
of proteins including signal transduction molecules (Thery et al, 2001; Blanchard et 
al., 2002)，MHC molecules (Van Niel et al, 2001; Wolfers et al., 2001; Blanchard et 
cd., 2002), and tetraspanins (Escola et al., 1998; Zitvogel et al., 1998; Heijnen et al., 
1999; Thery et al., 1999; Van Niel et al.’ 2001; Blanchard et al., 2002; 
Vincent-Schneider et al” 2002). Tetraspanins can interact with many protein partners 
such as integrins (Thery et al, 2002), which have been suggested to be important in 
the cellular attachment and intracellular signaling that are responsible for the 
proliferative potential of cardiomyocytes (Maitra et al., 2000). Moreover, one of the 
tetraspanins found in exosomes is CD81，which has been described to be a part of the 
IFITMl multimeric complex on the surface of B cells (Maecker et al” 1997; Escola 
et al., 1998). Therefore, further studies, for example, immunoelectron microscopy 
and double staining of organelles like Golgi apparatus or endoplasmic reticulum are 
definitely required to investigate the cellular localization of IFITM 1-3 proteins in 
H9C2 cells. 
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4.3 Induction by interferons-a，p and y 
The IFITM gene family is highly inducible by both type I (a and P) and type II (y) 
interferons (Friedman et al., 1984; Kelly et al., 1985). Three functional members of 
the family have been isolated on a genomic DNA fragment of less than 7 kilobases 
(kb) in rats: IFITMl, IFITM2 and IFITM3. The promoter or enhancer of each family 
member contains either multiple interferon-stimulated response elements (ISREs) or 
gamma-activating sequences (GAS), which confer responsiveness to interferons 
(Reid et al., 1989). Gene expressions of IFITMl, IFITM2 and IFITM3 have been 
shown to be promoted by type I (a and P) and type II (y) interferons (Chen et al, 
1984; Kelly et al, 1985; Knight et al, 1985; Jaffe et al., 1989; Reid et al., 1989; 
Evans et al.’ 1990; Lewin et al., 1991; Evans et al., 1993). 
Our real-time PCR results demonstrated different responsiveness of IFITMl, 
IFITM2 and IFITM3 in the presence of type I (a and P) and type II (y) interferons in 
H9C2 cardiomyoblast cells. IFITMl was moderately induced in response to type I 
interferons and significantly upregulated by type II interferon. Expression of IFITMS 
was notably increased by type I interferons，but did not change significantly when 
exposed to type II interferon. IFITM2 was non-responsive to type I and type II 
interferons. The similar responsiveness of the three members towards interferon-a 
and interferon-p supports the notion that interferons-a and p share the common 
signaling pathways (Stark et al., 1998). 
Notably, IFITM2 was neither responsive to type I nor type II interferons in 
cardiomyoblasts, but it is interferon-inducible in other cell types (Lewin et al., 1991). 
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IFITM3 was not induced by interferon-y in H9C2 cells. However, the transcript level 
of IFITM3 is increased in the presence of the cytokine in other cell types (Lewin et 
al., 1991; Brem et al.’ 2003). Such different expression patterns of IFITM2 and 
IFITM3 in response to interferons in various cell types may be a consequence of cell 
type specificity to perform specialized physiological functions. However, another 
possibility of the variations of ISRE and GAS sequences in the promoter regions in 
different species cannot be excluded. Further investigations on the ISRE sequences 
of IFITM2 and IFITM3 in rats by deletion or mutagenesis are clearly required for 
determining their importance in the expression of these two genes. 
Interestingly, although interferon-p caused a more than 20-fold increase in the 
mRNA level of IFITM3, the upregulation of IFITM3 was not statistically significant. 
Such contrary result was because the fold change of induction of IFITM3 by 
interferon-p varied greatly among the 3 independent experiments and this turned out 
the p value was larger than 0.05. 
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4.4 Inhibition of DNA synthesis by interferons-a 
and p and IFITMl 
Interferons are cytokines that regulate a variety of biological effects and one of the 
profound properties of interferons is inhibition of proliferation. The 
interferon-induced growth inhibition affects different phases of the mitotic cycle, 
including a block in Gl , lengthening of the S phase or a general prolongation of the 
cell cycle (Kimchi, 1992; Hartwell et al, 1994; Murphy et al, 2001). It is not clear 
which genes are involved in cell cycle control induced by interferons although 
several studies link the IFITM family, a group of interferon-inducible proteins, to 
antiproliferative activity. Downregulation of the IFITM family genes correlates with 
tumor growth and metastasis (Evans et al., 1990; Bradbury et al, 1992; Hartwell et 
al.’ 1994). Conversely, induction of the IFITM family members is related to the 
growth arrest of tumors (Evans et al., 1990; Certa et aL, 2001). Furthermore, the cell 
surface antigen, Leu-13，encoded by IFITMl is a part of the protein complex 
involved in signaling transduction of antiproliferative activities (Bradbury et al,, 
1992). 
From our results, because interferons-a and p induced IFITMl and IFITM3 and 
interferon-y promoted IFITMl expression in H9C2 cells, we next asked whether 
interferons would possess inhibitory effects on proliferation in cardiomyoblasts. In 
general, both interferons-a and p remarkably decreased relative BrdU uptakes in the 
proliferation assay, maximally for 66% and 47% respectively, but interferon-y 
moderately increased the BrdU uptakes for 20% on average under relatively higher 
concentrations of the cytokine (20r|g/ml and 40rig/ml), but not under a lower 
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concentration (10r|g/ml). 
In parallel, we examined the mRNA and protein expression levels of PCNA after the 
interferon treatments. In consistent with the observations in the BrdU proliferation 
assay, no matter in terms of mRNA and protein levels, interferons-a and p reduced 
PCNA expression. Strikingly, the decrease in the relative BrdU incorporation and the 
protein level of PCNA by interferon-p was not in a dose-dependent manner, which 
might be explained by the dual effects of interferon-p on DNA synthesis depending 
on its concentration, similar to the divergent actions of tumor necrosis factor-a 
(TNF-a) on apoptosis in human neutrophils (Van den Berg et al, 2001) and nitric 
oxide (NO) on meiotic maturation of mouse cumulus cell-enclosed oocytes (Bu et al., 
2003) under different concentrations. Therefore, these findings further support that 
the treatment of interferons-a and p decreased cellular DNA synthesis. On the other 
hand, interferon-y slightly promoted PCNA mRNA expression, but its protein level 
remained fairly constant. One of possible reasons that may explain this unexpected 
result is gene expression regulated at the posttranscriptional level. In the presence of 
interferon-Y, the mRNA of PCNA degraded rapidly and this lead to the lower levels 
of translation. 
In addition, the cell number was assessed before and after the interferon-a and p 
treatments by the trypan blue exclusion assay. No significant cell death was observed 
after the treatments. Instead, interferons-a and (3 reduced the cell number in a 
dose-dependent fashion, from 40% to 70% and from 60 to 80% respectively, when 
compared to the untreated cells. Therefore, the decrease in the cell number as a 
consequence of the interferon treatments is due to decreased proliferation rather than 
increased cell death. 
110 
Chapter 4: Discussion 
For the reason that the IFITM family was interferon-inducible and the interferons 
resulted in growth arrest in H9C2 cardiomyoblasts, we then examined whether 
IFITMl, IFITM2 and IFITM3 would have similar inhibitory effects in the cardiac 
cells. From our results, overexpression of IFITMl reduced the relative BrdU uptakes 
by 12%, but IFITM2 and IFITM3 did not affect the relative BrdU incorporation 
significantly. In agreement with the proliferation assay results, there was a slight 
reduction in the PCNA expression in IFITM 1 -transfected cells, but not in IFITM2 
and IFITM3, suggesting that IFITMl inhibited DNA synthesis in H9C2 cells, though 
only to a small extent. One of the possible explanations is that transient transfection 
usually has a low efficiency, in our case, only about 20%-30%. However, 
construction of stable cell lines expressing the IFITM family seems not to be the best 
solution. Probably owing to the cell division arrest property of the IFITM family, 
other research groups (Evans et al., 1990; Brems et al, 2003) failed to generate the 
stable clones expressing IFITMl or IFITM3. Instead, viral infection of the IFITM 
family may be one of the good alternatives for further studies. Moreover, to further 
exclude the reduction of DNA synthesis in IFITMl-transfected cells as a 
consequence of variations in transfection efficiencies，transfection efficiencies of 
different samples can be normalized by binding to the His antibody. 
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4.5 Involvement of IFITM family in canonical 
Wnt pathway 
Wnt pathway is important in many cellular processes including differentiation, 
proliferation, cell-cell interactions, apoptosis and survival (De Robertis et al., 2000; 
Huelsken and Birchmeier, 2001; Moon et al., 2001; Yamaguchi, 2001). In vertebrates, 
canonical Wnt pathway, which uses P-catenin as a downstream molecule, has been 
demonstrated to play a positive role in proliferation in a range of cell types 
(Masckauchan et al” 2005; Rao et al； 2005; Sangkhathat et al, 2006; Zhong et al., 
2006) except cardiac cells, in which the effects of Wnt signaling on cell division 
have not been extensively explored. 
Conventional Wnt signaling causes P-catenin accumulation in a complex with the 
transcription factor T-cell factor/lymphoid enhancer factor (TCF/LEF) that regulates 
target gene expression. In the absence of Wnt signaling, the level of (3-catenin is kept 
low through degradation of cytoplasmic p-catenin. p-catenin is targeted for 
ubiquitination and degradation in proteosomes by paired phosphorylation through the 
serine/threonine kinases casein kinase I (CKI) and glycogen synthase 3(3 (GSK3p) 
(Polakis, 2002) bound to a scaffolding complex of axin and adenomatous polyposis 
coli (APC) protein (Cadigan and Nusse, 1997; Polakis, 2000). Activation of Wnt 
signaling leads to inhibition of GSK-3p activity, resulting in accumulation of 
cytoplasmic signaling p-catenin, which becomes available to bind the TCF/LEF 
family of transcription factors and to induce target gene expression (Cadigan and 
Nusse, 1997). Thus, the key factors in p-catenin signaling are its stabilization and 
accumulation in the cytoplasm. 
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On the other hand, the IFITM family has recently been shown to correlate with Wnt 
signaling cascade. IFITMl has been described as a potential target gene of the Wnt 
pathway during gastrulation. Recent studies have shown that during embryogenesis, 
BMP4 and Wnt/p-catenin signaling are able to control the expression levels of 
IFITMl, IFITM2 and IFITM3 (Saitou et al, 2003; Lickert et al, 2005). Also, during 
intestinal tumorigenesis, they are induced after activation of the Wnt/p-catenin 
signaling (Andreu et al.’ 2006). Additionally, BrG-1, a component of the 
chromatin-remodelling complex SWI/SNF, is required for IFITMl expression, 
suggesting that it plays an important role in regulating these genes (Huang et al.’ 
2002). BrG-1 is known to interact with P-catenin to promote target gene expression 
(Barker et al” 2001). Therefore, the regulation of IFITM gene expression seems to be 
complex. 
Our data showed that the protein level of p-catenin was remarkably decreased in 
IFITMl, IFITM2 and IFITM3-transfected H9C2 cells. In parallel, p-catenin was 
downregulated when exposed to interferons-a, p and y, which induced the IFITM 
family. The correlation of the IFITM family and p-catenin expression implies that the 
IFITM family may be involved in the canonical Wnt signaling. Overexpression of 
IFITMl, IFITM2 and IFITM3 resulted in an accelerated degradation of the 
endogenous p-catenin in cardiomyoblasts, leading to the hypothesis that the IFITM 
family participates in a negative feedback loop in Wnt/p-catenin pathway, similar to 
Axin2, which is involved in the segmentation clock during somitogenesis (Yan et al, 
2001; Jho et al” 2002; Lustig et al., 2002; Aulehla et al., 2003) and p-transducing 
repeat-containing protein (p-TCRP), which plays an important role in p-catenin/TCF 
and NFKB-dependent signaling (Spiegelman et al” 2000). 
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Interestingly, overexpression of the IFITM proteins unexpectedly reduced the protein 
level of p-catenin to a large extent although the transfection efficiency was only 
20-30%. Because of the similar localization patterns of the IFITM proteins in H9C2 
cells with that of IFITM3 in other cell types (Brem et al,, 2003; Ropolo et al, 2004)， 
we speculate that the proteins are localized in exosomes. Meanwhile, Brem et al. has 
proposed a model of the cell-to-cell transfer of antiproliferative activities of IFITM3 
in melanoma cells via exosomes (Brem et al” 2003). The IFITM3 proteins in 
cultured melanoma cells are exported in multivesicular compartments to the cell 
surface and the antiproliferative signals are transmitted to the nucleus. A portion of 
the IFITM3-containing exosomes can bind to non-stimulated cells where 
transmission of the antiproliferative signals between the cells occurs. In this way, the 
IFITM3 activity can be amplified by the transfer system. However, further studies 
are certainly essential to investigate whether such transfer system of the IFITM 
activity occurs in cardiac cells and results in an accelerated degradation of p-catenin. 
As mentioned before, activation of the Wnt pathway results in the nuclear 
accumulation of P-catenin and increased transcription of Wnt/p-catenin target genes, 
including proliferation-related genes like c-myc (He et a!., 1998), c-jun (Mann el al., 
1999) and cyclin D1 (Shtutman et al, 1999; Tetsu，1999). Cyclin D1 regulates 
progression through G1 checkpoints in the cell cycle and low cyclin D1 expression is 
usually associated with cell cycle arrest (Sherr, 1995). Decreased cyclin D1 
expression was observed in interferon a-, (3- and y-treated H9C2 cells while 
degradation of p-catenin was increased after the treatments. This observation is in 
agreement with our hypothesis that interferons inactivate the Wnt/p-catenin pathway, 
leading to p-catenin degradation. 
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It is generally believed that a decrease in cyclin D1 expression is concomitant with a 
reduction of DNA synthesis. Interestingly, in interferon-y treated cells, although an 
increase of DNA synthesis was observed, the expression of cyclin D1 was 
remarkably reduced. Conventionally, the function of cyclin D1 is to regulate the cell 
cycle by activating the G1 kinases (Sherr, 1995). However, another role of cyclin D1 
recently suggested is to act as a transcriptional regulator in a kinase-independent 
manner (Dey and Li, 2000; Coqueret, 2002; Baker et al., 2005). Therefore, cyclin D1 
is more than a cell cycle regulator and may have multiple functions. 
In the mean time, when transfecting interferon-stimulated IFITMl, IFITM2 and 
IFITMS into H9C2 cells, cyclin D1 expression did not change significantly, but the 
protein level of p-catenin was remarkably reduced at the same time. One of the 
possible explanations for this unexpected result may be due to regulation of cyclin 
D1 by multiple signaling pathways. In addition to the canonical Wnt signaling, 
evidence has shown that the expression of cyclin D1 is regulated and altered by other 
signaling pathways, including STAT (Leslie et al.’ 2006), protein kinase C-a (PKC-a) 
(Hizli et al.’ 2006) and mitogen-activated protein kinase kinase/extracellular-signal 
regulated kinase (MEK/ERK) (Talarmin et al.’ 1999). 
Our preliminary data demonstrated that the expression of the IFITM genes is related 
to the Wnt pathway. However, the effects of Wnt/p-catenin signaling on the IFITM 
family should be further confirmed by investigating the IFITM family expression 
after activation of Wnt signaling by the treatment of Wnt3a or lithium chloride, an 
inhibitor ofGSK3(3 (Hedgepeth et al., 1997). 
115 
Chapter 4: Discussion 
^^LHP 
� O k i P l 
Destruction Complex ^ ^ ^ 
Figure 4.1 Canonical Wnt Signaling. In the absence of Wnt ligands ("OFF"), 
Dishevelled (Dsh) is inactive and glycogen synthasae kinase 3p (GSK3p) is active. 
Phosphorylation of p-catenin is believed to be a major step in destabilizing p-catenin. 
Association with adenomatous polyposis coli/glycogen synthasae kinase p 
(APC/GSK3P) complex targets P-catenin for degradation by the 
ubiquitin-proteosome pathway. Meanwhile, T-cell factor (TCF), a transcription factor, 
is bound its DNA-binding site in the nucleus where it is able to repression the 
expression of downstream genes. In the presence of a Wnt signal ("ON"), Dsh 
becomes activated, which then leads to inactivation of GSK3p. p-catenin fails to be 
phosphorylated and thus is no longer targeted to the ubiquitin-proteosome 
degradation pathway. Instead, P-catenin accumulates in the cytoplasm and thus enters 
the nucleus, where it alleviates its repression of the target genes and provides a 
transcriptional activation domain (Adapted from Willert and Jones, 2006). 
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4.6 Other possible pathways involved 
In addition to STAT, JAK and Wnt signaling, interferons and the IFITM family 
probably interfere with other signaling pathways. Phosphatidylinositol-3'-OH kinase 
(PI3K) and downstream effectors as Akt (a serine/threonine kinase) and nuclear 
factor kB can be activated by interferon-? and interferon-a/p (Stancato et al,, 1997; 
Sakatsume et al” 1998; David, 2002; Takaoka et al., 2003). Additionally, it has also 
been shown that p38 mitogen-activated kinase (MAPK) pathway is required for full 
interferon-induced ISRE and GAS element dependent transcription (Uddin et al., 
1999). MAPK or ERK2 interacts with the a-subunit of interferon-a/p receptor in 
vitro and in vivo. Treatment of cells with interferon-P induces phosphorylation and 
activation of MAPK and leads to MAPK and STATl coimmunoprecipitation. 
Furthermore, expression of dominant negative MAPK inhibits interferon-P induced 
transcription (David et al., 1995). Therefore，MAPK appears to regulate interferon-a 
and interferon-p activation by modifying the JAK-STAT signaling cascade. Studies in 
primary human cell lines have convincingly underscored the critical role of p38 
MAPK in interferon-induced growth inhibitory activity (Verma et al” 2002). 
Therefore, the interferon signaling and the regulation of the IFITM family proteins 
are complex and the basis of the cross talk between these pathways and the 
interferon-inducible IFITM proteins requires further clarification. 
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Chapter 5 
Future Prospects 
5.1 Production of antibodies 
We detected the expression of IFITM, IFITM2 and IFITM3 only on the mRNA level. 
However, the final active products of functional genes are proteins. Therefore, to 
further characterize and investigate the significance of the IFITM family in cardiac 
cells, production of antibodies by injection of synthetic peptides or purified proteins 
into animals like rabbits is necessary. 
5.2 Silencing or knockout approach 
IFITMl, IFITM2 and IFITM3 were found to be upregulated during rat myocardial 
development and differentiation of H9C2 cells. We employed overexpression 
approach in our studies to study the inhibitory effects of the proteins on the cardiac 
cells. However, silencing the IFITM family by RNA interference or generation of 
knockout mice will provide us a more comprehensive picture on the role of the 
proteins in heart development. 
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5.3 Target genes of Wnt/p-catenin signaling 
In our studies, we studied the effects of the IFITM family on p-catenin expression. 
Our preliminary data suggests that the expression of IFITMl, IFITM2 and IFITM3 
correlates with p-catenin degradation and the IFITM family may participate in a 
negative feedback loop in the Wnt/p-catenin signaling pathway in cardiomyoblasts. 
However, we did not study the expression of the IFITM family in the presence of 
Wnt signals. To study whether the IFITM proteins are the potential target genes of 
the Wnt pathway in cardiac cells, the effects of Wnt/p-catenin signaling on the 
IFITM family can be examined by activation of Wnt signaling by the treatment of 
Wnt3a or lithium chloride, an inhibitor of GSK3p. 
5.4 Other signaling pathways involved 
Beside Wnt pathway, the regulation or the activity of the IFITM family may possibly 
also involve other signal transduction pathways, for example, MAPK, NFKB, J A K 
and STAT. Studies of the IFITM family expression after treatments of the cardiac 
cells with the corresponding inhibitors of the signaling pathways investigated may 
provide us some insights of which signaling cascades are involved and how they 
interact with each other. 
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5.5 Use of primary cardiomyocytes 
We performed our studies in H9C2 cells, which are derived from rat myoblasts. 
However, some properties of the cell line may be different from the rat 
cardiomyocytes, which can be stimulated to beat in vitro. Therefore, in the future, 
primary culture of rat cardiomyocytes should be used for examining the role and the 
activity of the IFITM family in rat hearts. 
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Restriction Map and Multiple Cloning Site (MCS) of pEGFP-CI. All restriction sites shown are unique. The Xbs I and 
Bel I sites (•) are methylated in the DNA provided by BO Biosciences Clontech. tf you wish to digest the vector with these 
enzymes, you will need to transform the vector into a danr host and make fresh DNA. 
Description 
pE6FP-C1 encodes a red-shifted variant of wild-type GFP (1-3) which has been optimized for 
brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 488 nm; 
emission maximum = 507 nm.) pEGFP-C1 encodes the GFPmutI variant (4) which contains the 
double-amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the 
EGFP gene contains more than 190 silent base changes which correspond to human codon-usage 
preferences (5). Sequences flanking EGFP have been converted to a Kozak consensus translation 
initiation site (6) to further increase the translation efficiency in eukaryotic cells. The MCS in pEGFP-
C1 is between the EGFP coding sequences and the SV40 poly A. Genes cloned into the MCS will 
be expressed as fusions to the C-terminus of EGFP if they are in the same reading frame as EGFP 
and there are no intervening stop codons. SV40 polyadenylation signals downstream of the EGFP 
gene direct proper processing of the 3' end of the EGFP mRNA. The vector backbone also contains 
an SV40 origin for replication in mammalian cells expressing the SV40 T-antigen. A neomycin 
resistance cassette (Neo'), consisting of the SV40 early promoter, the neomycin/kanamycin 
resistance gene of Tn6, and polyadenylation signals from the Herpes simplex virus thymidine kinase 
(HSV TK) gene, allows stably transfected eukaryotic cells to be selected using G418. A bacterial 
promoter upstream of this cassette expresses kanamycin resistance in E. coli. The pEGFP-CI 
backbone also provides a pUC origin of replication for propagation in E. coliand an f1 origin for single-
stranded DNA production. 
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Restriction Map and Multiple Cloning Site (MCS) of pEGFP-NI Vector. All restriction sites shown are unique. The Not I 
site follows the EGFP stop codon. The Xba I site (*) is methylated in the DNA provided by BD Biosciences Clontech. If you 
wish to digest the vector with this enzyme, you will need to transform the vector into a danr and make fresh DNA. 
Description 
pEGFP-NI encodes a red-shifted variant of wild-type GFP (1-3) which has been optimized for 
brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 488 nm; 
emission maximum = 507 nm.) pEGFP-N1 encodes the GFPmutI variant (4) which contains the 
double-amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the 
EGFP gene contains more than 190 silent base changes which correspond to human codon-usage 
preferences (5). Sequences flanking EGFP have been converted to a Kozak consensus translation 
initiation site (6) to further increase the translation efficiency in eukaryotic cells. The MCS in 
pEGFP-NI is between the immediate early promoter of CMV {P^^ J and the EGFP coding 
sequences. Genes cloned into the MCS will be expressed as fusions to the N-terminus of EGFP if 
they are in the same reading frame as EGFP and there are no intervening stop codons. SV40 
polyadenylation signals downstream of the EGFP gene direct proper processing of the 3' end of the 
EGFP mRNA. The vector backbone also contains an SV40 origin for replication in mammalian cells 
expressing the SV40 T antigen. A neomycin-resistance cassette (Neo'), consisting of the SV40 early 
promoter, the neomycin/kanamycin resistance gene of Tn5, and polyadenylation signals from the 
Herpes simplex virus thymidine kinase (HSV TK) gene, allows stably transfected eukaryotic cells to 
be selected using G418. A bacterial promoter upstream of this cassette expresses kanamycin 
resistance in E. coli. The pEGFP-N1 backbone also provides a pUC origin of replication for 
propagation in E. co//and an f1 origin for single-stranded DNA production. 
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